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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with no
effective therapies. While abundant genetic, histological, and experimental evidence links
the beta-amyloid (Aβ) peptide to disease onset and progression, the mechanisms behind
neuronal dysfunction in AD are not completely understood.
It is now clear that AD is a complex, multifactorial disease characterized by vascular
dysfunction, prothrombotic state, and inflammation, but whether these conditions are a
cause or consequence of disease is debated. Prothrombotic and inflammatory states can
contribute to alterations in cerebral blood flow resulting in hypoperfusion. Since neuronal
function is dependent on an uninterrupted blood supply sustained by a healthy vasculature,
agents capable of eliciting thrombosis and/or inflammation could play a key role in AD onset
and progression.
The contact activation system, initiated by activation of the plasma protein FXII, is
capable of launching both thrombotic and inflammatory pathways. I investigated whether Aβ
could directly induce these pathways by interacting with FXII in vitro, in AD mouse models,
and in AD patients. A prothrombotic state may also result from reduced clot degradation, as
seen in mouse models of AD. I therefore investigated the mechanism by which clots formed
in the presence of Aβ are structurally altered and resistant to degradation.

I established the ability of Aβ to initiate prothrombotic and inflammatory processes via
activation of the FXII-driven contact system, and provided evidence for these processes in
AD patients and mouse models. I also defined the regions involved in Aβ-fibrinogen binding
and elucidated the mechanism by which this interaction results in delayed fibrinolysis. My
results suggest new pathogenic mechanisms, diagnostic tests, and therapeutic targets for
AD.

To my grandmother
Galina A. Lavnikova
March 7, 1922 – May 22, 2011
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CHAPTER 1. INTRODUCTION
1.1. Alzheimer’s disease: demographic and clinical features
Alzheimer’s disease (AD) is the most common type of dementia, affecting over 5.2
million Americans and 26 million people worldwide. Age is the greatest risk factor: one in
nine people age 65 and over (11%) and one third of those age 85 and over (32%) have AD1.
As the global population achieves higher longevity due to advances in medicine, the
prevalence of AD will continue to increase. By 2050, the number of Americans age 65 and
over with AD is projected to triple to 13.8 million if treatments to prevent or slow disease are
not developed. The disease is and will continue to be an immense financial burden: the cost
of care for individuals with AD is projected to increase from $203 billion in 2013 to $1.2
trillion in 20501.
At its earliest stages, AD is clinically characterized by deficits in the ability to learn and
remember new information. Symptoms progress to include impairment of semantic memory
(concept-based knowledge), executive function (problem solving, planning, and execution),
and visuospatial skills2. In late stages of disease, brain regions responsible for controlling
life-sustaining functions become affected, leading to death. Neuropathologically, AD is
characterized by the accumulation of the peptide beta-amyloid (Aβ) in the brain parenchyma
(plaques)3 and by the intraneuronal accumulation of filamentous hyperphosphorylated tau
protein (tangles)4. In addition to these diagnostic criteria, other histological changes found in
AD brains include vascular pathology, neuroinflammation, dystrophic neurites, and brain
atrophy. The etiology of AD is complex and still poorly defined. Despite decades of research,
the initiating event(s) behind neuronal dysfunction remain unclear. Many theories have
emerged from the study of the neuropathological hallmarks described above, with most
identifying the Aβ peptide as a critical player in AD pathogenesis.
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1.2. AD etiology: Aβ hypothesis
Aβ is proteolytically derived from the ubiquitously expressed transmembrane protein
amyloid precursor protein (APP). Cleavage of APP by the aspartyl protease β-secretase
creates the N-terminus of the Aβ peptide. Release of Aβ is mediated by the γ-secretase
catalytic component presenilin, which cleaves the remaining portion of APP at one of
several sites, creating a 39 to 43 amino acid Aβ peptide (Figure 1.1). The most common
form of Aβ generated is 40 amino acids long (Aβ40), with the 42 amino acid peptide (Aβ42)
considered to be the more pathogenic form5.
Normally, the generation of Aβ in the brain is balanced by its clearance, which is
mediated by proteolytic degradation6, cell-mediated clearance7,8, perivascular drainage9, and
transport across the blood-brain barrier (BBB) into the circulation10. A rise in Aβ
concentration leads to the formation of soluble Aβ oligomers, with subsequent fibrillization
and deposition in the form of plaques11 (Figure 1.1). Mutations in genes resulting in
increased production of Aβ or in the production of Aβ with decreased potential for clearance
are associated with elevated AD risk, providing a genetic link between Aβ and AD. For
example, mutations in APP, presenilin 1, or presenilin 2 induce altered Aβ production and
are responsible for an early onset, autosomal dominant form of the disease12. Furthermore,
triplication of the APP-bearing chromosome 21 in Down Syndrome results in increased Aβ
production, early Aβ plaque deposition, and dementia in 50-70% of individuals by age 607013.

2

Figure 1.1. Production of Aβ from APP. The ubiquitously expressed transmembrane
protein APP undergoes processing by β- and γ-secretases to release C-terminal soluble
APP (sAPP), the Aβ peptide, and an N-terminal intracellular domain (ICD). Aβ can selfaggregate, resulting in the formation of dimers, various oligomeric forms, protofibrils, and
fibrils.
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In contrast to these early-onset AD cases, it is thought that the vast majority of sporadic
(late-onset) AD stems from defective Aβ clearance and not increased Aβ production14-16.
Indeed, the strongest genetic risk factor for late-onset AD is apolipoprotein E (APOE)
genotype, with individuals carrying the APOE ε4 allele being at an increased risk of AD
compared to ε3 and ε2 carriers17,18. While the role of ApoE in AD is complex and not fully
understood, one aspect of its function is that it disrupts the transport of parenchymal Aβ
across the BBB by LRP1 receptors, with the ε4 isoform disrupting the efficiency of Aβ
clearance more than ε3 and ε219.
Correlations between Aβ accumulation and AD at both a histological and genetic level
support the “Aβ hypothesis of AD,” which states that a chronic imbalance in production
versus clearance of Aβ leads to its gradual accumulation in the brain, which over the many
years of AD development results in pathological changes characteristic of AD, including
microgliosis, astrocytosis, neuronal dysfunction, and cognitive impairment11. The idea that
Aβ accumulation can result in AD-related pathological and clinical changes is supported by
experimental evidence of Aβ-mediated toxicity. Aβ oligomers induce neuronal mitochondrial
dysfunction20, synaptic dysfunction21-23, and directly promote neuronal death21. Aβ deposits
trigger microglial and astrocytic activation, which can contribute to neuronal dysfunction
through inflammatory processes24. Thus, neuronal dysfunction due to Aβ’s direct or glial cellmediated toxicity can cause cognitive decline. However, Aβ deposits are also found in
neurologically normal individuals25-27, indicating that Aβ does not always induce neurotoxicity,
and suggesting that other factors contribute to AD onset.
1.3. AD etiology: vascular hypothesis
A healthy brain vasculature is critical for neuronal viability and cognitive function.
Oxygen and nutrients are supplied to the brain by arteries, which branch into arterioles and
finally into capillaries. Capillary walls mediate exchange of substances between the
4

circulation and brain parenchyma and constitute the BBB. Brain function is dependent on a
tightly regulated BBB and on consistent cerebral blood flow (CBF)28, which can be
dramatically affected by very small changes in cerebral vessel biology and structure29. While
cerebrovascular dysfunction has traditionally been thought to cause a distinct disease called
vascular dementia, a large body of evidence now indicates that significant overlap exists
between vascular dementia and AD, blurring this distinction30. Indeed, cerebrovascular
pathology is present in virtually all AD patient brains upon autopsy31-36 and BBB dysfunction
is increasingly recognized as an important aspect of AD pathology28,37-39, but whether these
changes play a causal role in AD or are simply co-morbidities is still debated.
The idea that vascular pathologies may be causative in AD stems from evidence that
they precede AD development. Conditions associated with vascular disease such as
diabetes, hypertension, hypercholesterolemia, atherosclerosis, silent brain infarcts, and
white matter lesions increase the risk of developing AD40-44, with nearly all of them present
not only at AD onset but also decades before any loss of cognitive function develops41.
Many of them can compromise CBF and induce brain hypoperfusion29, which are observed
early in the course of AD28,45,46. Disturbances in CBF and brain perfusion can lead to BBB
dysfunction, dysregulation of nutrient transport, neuronal dysfunction, and eventually
cognitive decline41,47. Hypoxia and energy deficits resulting from hypoperfusion can
accelerate Aβ deposition, increase tau hyperphosphorylation, impair BBB functions,
precipitate neuronal loss, and produce cognitive dysfunction46,48-50, all of which are
pathological hallmarks of AD. Even a relatively mild restriction in blood supply to brain tissue
causes long-term dysfunction of synaptic transmission51, underscoring the idea that small
deficits in oxygen and nutrient supply can over time have significant effects.
The presence of morphological abnormalities in the AD brain vasculature, the
epidemiologic connections between vascular disease risk factors and AD risk, and the
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potential mechanistic connections between vascular and neuronal dysfunction provide a
basis for an alternative theory known as the “vascular hypothesis of AD,” which states that
deficiencies in vascular function and CBF gradually lead to the pathological and molecular
characteristics of the disease29,41. Thus, the “Aβ hypothesis” identifies Aβ as a primary driver
in AD, while the “vascular hypothesis” identifies vascular dysfunction as a cause of AD
neuropathology and symptoms. But what exactly causes vascular dysfunction in individuals
at risk for AD?
In this thesis, I would like to propose that Aβ itself could drive the vascular changes that
may lead to AD onset and progression, providing a link between the Aβ and vascular
hypotheses. Exploring this connection requires the introduction of two additional pathologic
states associated with AD.
1.4. Prothrombotic state in AD
In keeping with a link between AD and vascular dysfunction, accumulating evidence
suggests that AD patients and mouse models exhibit a prothrombotic or hypercoagulable
state, defined as an increased tendency toward clot formation. Clot formation is mediated by
activated platelets and the coagulation cascade, which involves the sequential activation of
a series of factors resulting in the production of thrombin. AD patients have elevated plasma
levels of activated Factor VII, prothrombin fragment 1+2, von Willebrand Factor52,53, and
activated platelets54,55, all of which reflect or promote increased thrombin generation. The
existence of a prothrombotic state in AD would be expected to increase the incidence
thrombotic events. Indeed, AD patients are at a higher risk for microinfarcts56,57 and stroke58
compared to non-demented controls, microinfarct number correlates with cognitive decline 57,
and AD mouse models have a greater propensity to form thrombi59,60.
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An important question is whether the prothrombotic state in AD patients is a cause or
consequence of disease. Evidence for a causative role comes from epidemiological studies
suggesting that prothrombotic states may contribute to disease onset and progression.
Older adults with increased D-dimer and prothrombin fragment 1+2 levels, both markers of
increased thrombin generation, are at higher risk for cognitive decline61, and increased
levels of coated platelets (a highly pro-coagulant subset of activated platelets62) correlate
with future AD severity63 and progression from MCI to AD64. Conditions characterized by
hypercoagulability such as factor V Leiden (a prothrombotic mutation in factor V)65, elevated
plasma homocysteine levels66-68, elevated plasma fibrinogen levels69, silent brain infarcts40,
and stroke70-72 place individuals at increased risk for AD. The hypothesis that a
prothrombotic state contributes to AD is also supported by improvements in AD pathology
and memory in AD patients73-75 and mouse models76,77 following treatment with
anticoagulants.
1.5. Proinflammatory state in AD
Inflammation is a well-established component of AD pathology supported by proteomic,
histological, genetic, and epidemiological evidence24,78. Inflammation in the AD brain
parenchyma is characterized by increased levels of activated microglia and astrocytes (the
cellular mediators of inflammation in the brain) as well as by increased levels of complement
system components and cytokines24. Chronic activation of astrocytes diminishes their
capacity to support neuronal health79,80, and the release of proinflammatory molecules from
chronically activated microglia and astrocytes combined with chronic complement activation
can directly induce neuronal toxicity81. Inflammation in AD is observed not only in the brain
parenchyma, but also in the periphery: AD plasma and serum have elevated levels of
circulating proinflammatory cytokines, chemokines24,78, and acute phase proteins, and AD
blood cells produce increased levels of cytokines78,82. The idea that peripheral inflammation

7

can contribute to and/or reflect neuroinflammation and neuropathology is supported by
studies in AD patients and mouse models demonstrating that elevated circulating levels of
proinflammatory molecules correlate with increased microglial activation, neuronal loss, and
cognitive decline78.
Whether inflammation is a primary driver of AD, a toxic consequence of other AD-related
processes, or a protective response delaying AD onset is debated83. However, several lines
of evidence support a role for inflammation in driving AD onset and progression. Mouse
models of AD show microglial activation prior to Aβ plaque deposition84,85, microglial
activation is seen in prodromal AD86,87, and is increased in early to moderate AD compared
to controls88,89. Further support comes from studies showing that peripheral markers of
inflammation increase the risk of AD90, that incidence of systemic infections increase the risk
of dementia91, and that cognitive impairment in AD individuals is exacerbated during and
after systemic infection92. Finally, numerous epidemiological studies show that long-term
nonsteroidal anti-inflammatory drug use reduces AD risk24.
1.6. Contribution of prothrombotic and inflammatory states to vascular dysfunction
Thrombosis and inflammation can contribute to vascular dysfunction through multiple
mechanisms. Thrombus formation in arterioles decreases CBF in downstream capillaries93,
while thrombosis in venules disrupts local CBF and decreases CBF in upstream capillaries94.
Chronically decreased CBF can lead to vascular endothelial cell remodeling, endothelial cell
death95, and capillary collapse47. Thrombin itself can mediate endothelial cell permeability in
vitro96-98 and precipitate BBB dysfunction and breakdown in vivo99,100. BBB dysfunction
results in leakage of plasma proteins into the brain parenchyma, leading to vessel wall
thickening and subsequent functional deterioration101,102. Furthermore, thrombin binding to
protease activated receptors on endothelial cells promotes the release of proinflammatory
cytokines103,104, thereby contributing to inflammatory processes.
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Inflammation-induced vascular dysfunction may stem from changes in the ability of
chronically activated astrocytes to control vascular tone and BBB function79,80 as well as
from a proinflammatory state in the periphery. Circulating proinflammatory molecules such
as cytokines, activated complement components, and bradykinin can modify vascular
endothelial cell function and increase BBB permeability105-109. Indeed, mouse models with
systemic inflammation have increased susceptibility to BBB permeability110-112. The ability of
inflammatory processes to elicit clinically-relevant vascular dysfunction is illustrated by the
etiology of vascular disease in humans. Inflammation-induced endothelial activation and
leakage of blood components through a compromised endothelium can lead to chronic
vascular diseases such as atherosclerosis107,113 and cerebral small vessel disease114,115,
both characterized by vessel narrowing and stiffness107,115,116.
Thus, changes to vascular biology, structure, and permeability induced by thrombotic
and inflammatory mediators could be a key mechanism behind the vascular dysfunction,
BBB dysregulation, and CBF reduction implicated in the initiation and/or progression of AD.
1.7. A possible role for Aβ in thrombosis and inflammation
If dysregulated coagulation and inflammation play a role in inducing and/or exacerbating
vascular pathology, pathways capable of triggering these processes are of great interest to
AD etiology. The contact activation system, which can launch both prothrombotic and
proinflammatory pathways, is initiated when the plasma protein factor XII (FXII) is exposed
to negatively charged surfaces (contact activation)117. Contact activated FXII (FXIIa) cleaves
plasma prekallikrein to generate plasma kallikrein, which in turn cleaves high molecular
weight kininogen (HK) to release the proinflammatory mediator bradykinin (Figure 1.2,
kallikrein-kinin system). In addition to cleaving prekallikrein, FXIIa also activates factor XI
(FXI) in the intrinsic coagulation cascade leading to thrombin generation, the conversion of
fibrinogen to fibrin, and clot formation (Figure 1.2, intrinsic coagulation pathway). Activation
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of the contact system also produces numerous proteases (including FXIIa, kallikrein, FXIa,
and thrombin) capable of complement system activation118-120 (Figure 1.2). In AD, a possible
surface for FXII activation could be Aβ, which has been shown to stimulate FXII-dependent
plasma kallikrein activity121,122 and HK cleavage121,123 in vitro.
Thrombotic potential is mediated not only by agents capable of modulating the
coagulation cascade, but also by factors affecting the physical and biochemical stability of
the forming fibrin clot, which is very sensitive to the conditions under which it is formed124. In
this regard, binding of Aβ to fibrinogen125 in the forming clot may further promote thrombosis
by inducing changes in clot structure and stability59.
The potential for interactions between Aβ and FXII and/or fibrinogen in vivo is supported
by studies placing Aβ at sites of possible thrombosis and inflammation at increased
concentrations. This includes locally elevated levels of Aβ at the luminal side of cerebral
capillary walls, where Aβ enters the blood through the BBB10, secretion of Aβ by activated
platelets126, and Aβ accumulation in atherosclerotic lesions127. Taken together, accumulating
evidence supports the hypothesis that Aβ may act as both an initiator of coagulation and
inflammation via interaction with FXII and as a modulator of clot stability via interaction with
fibrinogen.
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Figure 1.2. The contact activation system. Contact between FXII and negatively charged
surfaces produces activated FXII (FXIIa), which can lead to activation of the intrinsic
coagulation pathway (blue panel) and the plasma kallikrein-kinin system (green panel).
Activation of FXI to FXIa triggers a cascade of proteolytic reactions ultimately resulting in the
formation of thrombin, which mediates clot formation. Plasma kallikrein (PK) generated from
FXIIa-mediated plasma prekallikrein (PPK) activation further activates FXII (feedback
activation) and cleaves high molecular weight kininogen (HK), which releases bradykinin.
Proteases capable of initiating complement system activation are designated in red.
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1.8. Objectives
AD is an enormous and growing public health problem, due in large part to the fact that
there are no effective therapies. Major roadblocks to the treatment of AD are the lack of
adequate diagnostic tools and the absence of viable therapeutic targets, both stemming
from an incomplete understanding of the mechanistic basis of AD etiology and progression.
The induction of prothrombotic and inflammatory states by Aβ could explain the
epidemiological associations between AD, thrombosis, and inflammation. At the same time,
Aβ-mediated activation of inflammatory and prothrombotic processes could be the missing
link connecting the Aβ hypothesis with the vascular hypothesis of AD. Evaluation of the
possibility that Aβ could act as a trigger for thrombosis and inflammation by interacting with
plasma proteins FXII and fibrinogen is the focus of the work presented in this thesis. A
detailed understanding of these interactions may reveal new pathological mechanisms,
provide possibilities for earlier diagnosis, and pave the way for novel therapeutic targets in
AD.
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CHAPTER 2. MATERIALS AND METHODS
2.1. Identification of fibrinogen regions that interact with Aβ
Plasminogen was purified from human plasma (NY Blood Center) using lysinesepharose as described128, and co-purifying plasmin was inactivated with 10 mM diisopropyl
fluorophosphate (Sigma). Human plasminogen-free fibrinogen (Calbiochem; 5 mg/ml in 50
mM Tris, pH 7.4, 150 mM NaCl, 5 mM iodoacetamide) was incubated with 0.6 µM
plasminogen and 0.37 µM tPA (generously provided by Genentech) overnight at 37°C to
generate small fibrinogen degradation products (FDPs) or with 140 nM plasminogen and 20
nM tPA for 6 hours (hrs) at 37°C to generate large FDPs. Digestions were stopped with
aprotinin (Sigma). FDPs (500 µl) were incubated for 3 hrs at room temperature (RT) with
synthetic N-terminally biotinylated Aβ42 (Anaspec; 200 nM or 2 µM final concentration) in
phosphate buffered saline (PBS) adjusted to contain 500 mM NaCl, 0.01% NP-40 and
protease inhibitor cocktail (Roche), the Aβ-interacting peptides pulled down with
streptavidin-sepharose beads (Invitrogen) for 1 hr at RT, and the peptides eluted with
sample loading buffer and analyzed by SDS-PAGE on a 4-20% gradient gel (Life Sciences)
with colloidal blue staining (Invitrogen). Incubations that did not contain biotinylated Aβ42
served as a control for non-specific binding to the streptavidin-sepharose beads.
Mass spectroscopy was performed by the Rockefeller University Proteomics Resource
Center as follows: protein gel bands were excised from the SDS-PAGE. Gel bands were
reduced with 10 mM dithiothreitol (DTT) and alkylated with 55 mM iodoacetamide,
then digested with Sequence Grade Modified Trypsin (Promega) in ammonium bicarbonate
buffer at 37°C overnight. Digestion products were extracted twice with 0.1% trifluoroacetic
acid, 50% acetonitrile, and 1.0% trifluoroacetic acid. The extracted mixture was dried by
Speed-Vac and re-dissolved in 10 ml 0.1% trifluoroacetic acid. For LC-MS/MS analysis, the
Dionex U3000 capillary/nano-HPLC system directly interfaced with the LTQ-Obritrap mass
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spectrometer (Thermo Fisher), which was operated in the data-dependent acquisition mode
using Xcalibur 2.0.7 software. The MS/MS scans from each LC-MS/MS run were converted
from the .RAW file format to .DTA files using Bioworks 3.3.1 software. DTA files were
analyzed using the MASCOT software search algorithm.
2.2. MALDI-TOF mass spectrometry and Edman sequencing
MALDI-TOF mass spectrometry and Edman sequencing were performed by the
Rockefeller University Proteomics Resource Center. Coomassie blue-stained bands were
excised from SDS-polyacrylamide, destained with 200 mM ammonium bicarbonate in 50%
acetonitrile, and treated with 10 mM DTT in 0.1 M ammonium bicarbonate for protein
reduction. Free cysteine residues were alkylated with freshly made 55 mM iodoacetamide in
0.1 M ammonium bicarbonate. Tryptic digestion was performed with 25 ng/µl Sequence
Grade Modified Trypsin (Promega) in ammonium bicarbonate buffer for 16 hrs at 30°C with
agitation. Digestion products were cleaned and concentrated using micro-C18 ZipTip
(Millipore), mixed with 0.5 µl of 10 mg/ml α-cyano-4-hydroxysuccinnamic acid in 50%
acetonitrile, 0.1% (v/v) TFA, and applied onto a MALDI plate. MALDI mass spectra were
recorded with a PerSeptive Voyager-DE STR MALDI time-of-flight mass spectrometer
operated in the reflectron mode. The mass measurement accuracy with internal calibration
was, in general, better than 100 ppm. The measured peptide masses were used for
database searching with ProFound algorithm. Edman sequencing was performed using an
Applied Biosystems Procise sequencer.
2.3. Pulldown assay between Aβ and 49 amino acid fibrinogen β-chain fragment
A 49 amino acid fragment corresponding to fibrinogen β-chain residues 366-414
(TMTIHNGMFFSTYDRDNDGWLTSDPRKQCSKEDGGGWWYNRCHAANPNGR) was
synthesized at Rockefeller University’s Proteomics Resource Center. N-terminally
biotinylated Aβ42 (200 nM) or vehicle was incubated with the 49-mer (1 µM) in PBS
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containing 0.01% NP-40 and protease inhibitor cocktail (Roche) for 2 hrs at RT. Biotinylated
Aβ42 and its binding partners were pulled down using streptavidin-sepharose beads for 1 hr
at RT, washed, and eluted with sample buffer. Eluates were analyzed by SDS-PAGE on a 420% gradient gel followed by silver staining (Thermo Scientific).
2.4. Preparation and purification of fibrinogen fragment D
Fibrinogen fragment D was prepared and purified as described in 129. Briefly,
plasminogen-free human fibrinogen (Calbiochem) was reconstituted in 50 mM Imidazole, 5
mM CaCl2, 150 mM NaCl, pH 7.4 and treated with 5 mM iodoacetamide (Sigma). Fibrinogen
was digested with 0.01 mg TPCK trypsin (Pierce) per 1 mg fibrinogen for 4 hrs at 22°C.
Digestion was stopped with soybean trypsin inhibitor (0.03 mg soybean trypsin inhibitor per
1 mg fibrinogen). Fragment D was affinity purified using the GPRPC peptide (prepared at
the Rockefeller University Proteomics Resource Center) covalently immobilized on a
SulfoLink Coupling Resin column (Thermo Scientific). The column was equilibrated with 50
mM imidazole, 5 mM CaCl2, 150 mM NaCl pH 7.0, and fibrinogen degradation products
were applied to the column and allowed to incubate for 15 minutes (min) with end-over-end
rotation. The column was washed with 50 mM imidazole, 1 M NaBr, pH 7.2 and fragment D
eluted with 50 mM NaAc, 1 M NaBr, pH 5.3. Eluted fragment D was neutralized with 2 M Tris,
pH 8.0 and dialyzed into PBS. Affinity-purified fragment D was subjected to another step of
fast protein liquid chromatography (FPLC) purification using a Superose 12 gel filtration
column on an AKTA protein purification system (GE Healthcare), eluting in 50 mM Tris pH
7.0. The purity of the fragment D preparation was confirmed by SDS-PAGE followed by
colloidal blue staining.
2.5. Western blot analysis
Non-reduced or reduced samples were subjected to SDS-PAGE on 10% or 4-20%
gradient gels, transferred to polyvinylidene fluoride (PVDF) membranes (Millipore), and
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incubated in blocking buffer (5% milk in PBS containing 0.1% Tween-20 (PBS-T)) for 30 min
at RT. Membranes were incubated with primary antibody diluted in blocking buffer for 2 hrs
at RT or overnight at 4°C. After washing with PBS-T, membranes were incubated with HRPconjugated secondary antibodies in blocking buffer for 1 hr at RT. After washing,
membranes were incubated with chemiluminescent substrate (Perkin-Elmer or GE) and
exposed to film (Ewen-Parker). Blots were stripped with stripping buffer (Thermo Scientific)
when analysis with multiple antibodies was necessary. For quantification, film exposures
were chosen such that all bands were below saturation level, and images were imported into
ImageJ software130. The density of each band was measured by selecting a rectangular
area slightly larger than the band (the area of the rectangle was constant for all bands
corresponding to the same protein) and measuring mean pixel intensity for that area.
Rectangles of identical size were then used to measure background pixel intensity directly
above or below each band, which was then subtracted from the corresponding band’s pixel
intensity.
2.6. Pulldown assay between Aβ or Aβ fragments and fibrinogen fragment D
Synthetic N-terminally biotinylated Aβ fragments 1-16, 15-25, 17-40, 22-41, 1-40, and 142 (200 nM, Anaspec) were incubated with fibrinogen (1 nM) or fibrinogen fragment D (200
nM) for 1 hr at RT in 50 mM Tris pH 8.0 containing 500 mM NaCl, 0.01% NP-40 and
protease inhibitor cocktail. Streptavidin beads were added for 30 min, and elution was
conducted as described above and analyzed by Western blot using a polyclonal antibody
against fibrinogen (Dako). For some experiments, biotinylated Aβ42 (200 nM) was incubated
with varying concentrations of non-biotinylated Aβ17-42 and a pulldown assay performed as
described above. In some experiments, fibrinogen fragment D was biotinylated using SulfoNHS-biotin (Pierce). Pulldown assays were performed with biotinylated fragment D (200 nM)
and Aβ42 I31P or Aβ42 G37D (1 µM) in 50 mM Tris pH 7.4 containing 150 mM NaCl, 0.01%

16

NP-40, protease inhibitor cocktail, and 0.1% bovine serum albumin (BSA) as described
above. Western blots were probed with antibodies against fibrinogen (Dako) and Aβ (3D6,
Elan).
2.7. Crystallization of fibrinogen fragment D-Aβ42 complex
Fragment D crystals were obtained with the assistance of the Rockefeller University
Structural Biology Resource Center as described in 129. Briefly, crystals were obtained by
sitting drop vapor diffusion at RT from 50 mM Tris, pH 8.5, 70 mM CaCl2, 2 mM sodium
azide, 12-17% polyethylene glycol (PEG) 3,350 in drops of 10-20 µl, with fragment D
(prepared as described in Methods 2.5) at 15 mg/ml. Aβ42, Aβ42 G37D, Aβ42 I31P, and
Hylite fluor 555-Aβ42 (all from Anaspec) were reconstituted to 0.7-1.5 mg/ml in 50 mM Tris,
pH 8.5 with 0.12% NH4OH, then diluted 2-fold in 2X reservoir buffer (50 mM Tris pH 8.5, 4
mM sodium azide, 140 mM CaCl2, 34% PEG 3,350) to yield Aβ peptides in 1X reservoir
buffer. Fragment D crystals were then soaked in the various Aβ solutions (containing an
excess of Aβ over fragment D) for two weeks at RT, frozen in the N2 cryostream in reservoir
buffer without cryoprotection, and diffracted to 3.3 Å (for Aβ42-soaked crystals) at the
National Synchrotron Light Source, Brookhaven National Laboratory (Beam line X25,
wavelength = 1.1 Å). We also obtained data to 2.9 Å for crystals not subjected to soaking
(native crystals). Data reduction was performed using HKL2000 software131. Molecular
replacement was performed with PHENIX software (PHENIX-dev-1555) using the PDB entry
1FZA for fragment D132, resulting in successful determination of the phases and coordinates
of fragment D atoms. Refinement was performed with PHENIX software133.
2.8. Preparation of Aβ and control peptides for fibrinolysis experiments
Aβ42 (Anaspec) was reconstituted to 1 mg/ml in 50 mM Tris pH 7.4, 0.1% NH4OH and
stored at -80°C. Prior to use, Aβ42 was incubated at 37°C with shaking for 12 hrs to
generate a range of oligomeric species. Insoluble Aβ42 was removed by centrifugation at
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12,000 x g for 10 min134. The concentration of soluble Aβ42 was verified via bicinchoninic
acid assay (BCA), and a representative transmission electron microscope (TEM) image of
the Aβ42 preparation used is shown in Figure 3.5A. HiLyte Fluor 555-Aβ42 and HiLyte Fluor
555-Aβ(1-9) (Anaspec) were reconstituted to 0.5 mg/ml in the same buffer and not
incubated prior to use unless otherwise indicated.
Amylin (Anaspec) was reconstituted to 2 mg/ml in dimethyl sulfoxide (DMSO). Prior to
use, amylin was diluted to 0.2 mg/ml with 50 mM Tris pH 7.4 (10% DMSO final
concentration) and incubated for 24 hrs at 37°C with shaking. Presence of amyloid fibrils
was confirmed by TEM (Figure 3.5G) and Thioflavin T fluorescence (not shown).
2.9. Transmission Electron Microscopy
Samples were diluted to 0.1 mg/ml, applied to glow discharged CF200-Cu grids
(Electron Microscopy Sciences), washed three times with ultrapure water (UV-treated with a
Millipore system), and negatively stained with 2% uranyl acetate. Images were acquired
using a JEOL JEM 100CX Transmission Microscope at the Rockefeller University Electron
Microscopy Resource Center.
2.10. Preparation of fibrin monolayers
Fibrin monolayers were prepared in Fisherbrand High Binding 96-well plates (Fisher
Scientific) as described135,136. Wells were treated with 2.5% glutaraldehyde in 0.1 M sodium
bicarbonate buffer pH 9.5 for 2 hrs at 37°C. After washing with ultrapure water, 0.3 µM
fibrinogen in PBS + 1 mM CaCl2 (60 µl) was applied for 18 hrs at 4°C. Wells were washed 3
times with PBS, and free aldehyde groups were neutralized with 100 µl 0.3 M ethanolamine
pH 7.4 during a 1 hr incubation at RT. Wells were washed 3 times with PBS, and
immobilized fibrinogen was converted to fibrin with 1 U/ml thrombin (Sigma) in PBS (60 µl)
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for 1 hr at 37°C. Fibrin-bound thrombin was eluted with 0.5 M NaCl, and fibrin monolayers
were stored at 4°C in PBS + 20 mM lysine.
2.11. Clot turbidity analysis
Assays were performed at RT in Fisherbrand High Binding 96-well plates in triplicate
using a Molecular Devices Spectramax Plus384 reader. Clot formation was detected as a
change in absorbance at 350 nm, with readings taken every 30 seconds (s). For clot
formation and lysis, fibrinogen (1.5 µM) with or without Aβ42 (3 µM) was mixed with
plasminogen (125 nM-300 nM), α-thrombin (Sigma; 0.5 U/ml), tPA (0.15 nM-15 nM), and
CaCl2 (5 mM) in 20 mM HEPES (N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid)
buffer (pH 7.4) with 140 mM NaCl, in a volume of 150 µl. The absence of plasmin activity in
the plasminogen preparation was confirmed by chromogenic substrate assay (not shown).
In some experiments, Aβ42 I31P and 555-Hylite Fluor Aβ42 and 555 Hylite Fluor Aβ(1-9)
were used.
For lysis of pre-formed clots, fibrinogen (2.2 µM) with or without Aβ42 (5 µM) was mixed
with plasminogen (125 nM), thrombin (0.5 U/ml), and CaCl2 (5 mM) in 20 mM HEPES buffer
(pH 7.4) with 140 mM NaCl, in a volume of 100 µM. Clots were incubated at 37°C for 1 hr,
then overlaid with a 100 µl solution containing 10-50 nM tPA, 250 nM plasmin (Sigma) or 1
µM bovine TPCK trypsin (Thermo Scientific). Clots overlaid with plasmin and trypsin did not
contain plasminogen. Prior to lysis, some clots were overlaid with 5 µM Aβ42 for 1 hr, the
overlays removed, and the clot surface washed three times with HEPES buffer.
2.12. Enzyme activity
Assays were performed at RT in Fisherbrand 96-well plates with a reaction volume of
150 µl. For plasmin activity, chromogenic substrate Pefa-5329 (Centerchem; 530 µM) was
added to plasmin (440 nM) with various amounts of Aβ42. For tPA activity, chromogenic
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substrate S-2288 (Diapharma; 530 µM) was added to tPA (100 nM) with various amounts of
Aβ42. For tPA-mediated plasminogen activation, plasminogen (440 nM) and tPA (100 nM)
were mixed with various amounts of Aβ42, and Pefa-5329 was added to monitor plasmin
generation.
To monitor plasmin activity and clot turbidity simultaneously and under the same
reaction conditions, parallel clots were prepared containing fibrinogen (1.5 µM),
plasminogen (300 nM), tPA (0.15 nM) or streptokinase (Sigma; 0.75 nM), thrombin (0.5
U/ml), CaCl2 (5 mM) and either Pefa-5329 (400 µM) or buffer only (modified from 137,138).
Readings were taken at dual wavelengths of 405 nm (A405) and 350 nm (A350). Plasmin
activity was detected in the samples containing Pefa-5329 at A405, from which the signal
arising from the changing turbidity (A405) of the forming and lysing clot without Pefa-5329
was subtracted. Clot turbidity and plasmin activity were plotted together to best visualize the
temporal relationship of the two processes.
Fibrin monolayers were overlaid with 60 µl of Aβ42 (2 µM) or vehicle in PBS and
incubated for 18 hrs at 4°C. The Aβ was removed, and the well surface washed three times
with PBS containing 0.05% Tween-20. Fibrin monolayers or control wells were then overlaid
with 150 µM of plaminogen (300 nM) and tPA (1.5 nM), and plasmin activity measured with
530 µM of the chromogenic substrate Pefa-5329.
2.13. Clot structure and binding studies: Laser scanning confocal microscopy
Samples were visualized at RT using a Zeiss LSM 510 confocal laser scanning system
and a Zeiss Axiovert 200 microscope with a 40x-Axiovert 1.2/water objective (3x optical
zoom) at the Rockefeller University Bio-Imaging Resource Center. Laser scanning was done
in multi-track scanning mode with excitation at 488 nm and emission at 500-530 nm (for
Alexa Fluor 488 fibrinogen) and excitation at 543 nm and emission at 565-615 nm (for 555
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HiLyte Fluor Aβ). All images were acquired using LSM 510 version 3.2 software (Zeiss) 50
µm above the glass surface. Five µm z-stacks taken every 0.5 µm (11 slices per image)
were projected two dimensionally to produce the final image.
Aβ binding to fibrin(ogen): Clots (30 µM final volume) were formed in 1.5 mm glassbottom dishes (Mattek). Fibrinogen (2.7 µM) and Alexa-Fluor 488 fibrinogen (Invitrogen; 0.3
µM) were mixed with thrombin (0.5 U/ml) and CaCl2 (5 mM) in 20 mM HEPES (pH 7.4) with
140 mM NaCl with or without Aβ. For clots with Aβ, non-labeled Aβ42 (1.5 µM) was mixed
with HiLyte Fluor 555 Aβ42 (1.5 µM) or HiLyte Fluor 555 Aβ(1-9) (1.5 µM). Clots were
incubated in the dark at 37°C for 1 hr prior to imaging. For overlay experiments, clots formed
as described were overlaid with HiLyte Fluor 555 Aβ42 (3 µM), HiLyte Fluor 555 Aβ(1-9) (3
µM) or vehicle for 1 hr, the overlays removed, and the clot surfaces washed with HEPES
buffer. The fluorescent label does not alter Aβ’s ability to delay clot lysis (not shown). For
some experiments, clots were visualized in the absence of fluorescently labeled Aβ but with
Aβ42 or Aβ42 I31P (1.5 µM).
Plasminogen binding to fibrin: Clots (30 µM final volume) were formed in 1.5 mm glassbottom dishes with fibrinogen (3 µM), fluorescein isothiocyanate (FITC) labeled Gluplasminogen (Oxford Biomedical; 125 nM), thrombin (0.5 U/ml), CaCl2 (5 mM), with or
without Aβ42 (5 µM) in 20 mM HEPES (pH 7.4) buffer with 140 mM NaCl. Samples were
visualized as above, but using single track mode with excitation at 488 nm and emission at
500-530 nm. Five sections were captured from random locations in three separate control
and Aβ-influenced clots. Representative 5 µM z-stacks composed of 11 slices and projected
two dimensionally were also acquired for each control and Aβ-containing clot. FITCplasminogen binding to fibrin was analyzed using ImageJ130, with total fluorescence in each
section used as a measure of plasminogen binding.
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2.14. Plasminogen binding to fibrin monolayer: ELISA
Fibrin monolayers were incubated with Aβ42 (2 µM) or vehicle for 18 hrs at 4°C. Nonbound Aβ was removed and the monolayers washed with PBS with 0.05% Tween-20 three
times. Plasminogen (500 nM) was then applied to the monolayers in PBS with 4% milk and
0.01% Tween-20 for 2 hrs at 37°C. Plasminogen was removed, and monolayers washed
with PBS with 0.05% Tween-20 three times. Monoclonal plasminogen antibody 10A1 (Santa
Cruz; 1:2000) in PBS with 4% milk and 0.01% Tween-20 was applied to the monolayer for 1
hr at RT. After washing, HRP-conjugated anti-mouse antibody (GE Healthcare; 1:5000) in
the same buffer was applied for 1 hr at RT. After washing, the ELISA was developed using a
tetramethylbenzidine (TMB) peroxidase substrate (Vector Labs) and reactions stopped
using 1N H2SO4. Absorbance was measured at 450 nm. All conditions were tested in
triplicate.
2.15. Preparation of Aβ for FXII activation studies
Aβ42, Aβ40, and Aβ42 E22Q Dutch (Anaspec) monomers and oligomers were prepared
as in 139 with some modifications. Aβ peptides were monomerized by treatment with
hexafluoroisopropanol (Sigma-Aldrich). Monomerized Aβ was dissolved to 5 mM with
dimethyl sulfoxide (Sigma-Aldrich). For monomer (fresh) preparations, Aβ was dissolved to
100 µM in ultrapure ice-cold water and used immediately. For oligomers, Aβ in DMSO was
dissolved to 100 µM in Ham’s F12 medium (Caisson Labs) and incubated at 4°C for 16 hrs
with rotation. For fibrils, non-monomerized Aβ42 was dissolved into a minimum volume of
1% NH4OH, then adjusted to 200 µM with tris buffered saline (TBS) and incubated at 37°C
with shaking for 7 days. All Aβ preparations were confirmed by TEM.
2.16. Human blood collection and plasma preparation
Studies with human volunteers were approved by the Rockefeller University Institutional
Review Board or by the Karolinska Institute. Blood was drawn from 10 healthy volunteers
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giving informed, written consent using 21 gauge 0.75 inch butterfly needles (BD) with a
multi-adapter for S-Monovette (Sarstedt) into S-Monovette 5 ml tubes containing 1/10
volume 0.106 mM trisodium citrate solution at the Rockefeller University Hospital and
Karolinska Institute Hospital. To obtain platelet rich plasma (PRP), blood was centrifuged at
130 x g for 10 min at RT, and the top 1/2 of the PRP removed. To obtain platelet poor
plasma (PPP), blood was centrifuged twice at 2000 x g for 10 min at RT. PPP was frozen
immediately at -80°C. All experiments with PRP and PPP were repeated using plasma from
at least 3 volunteers.
2.17. Mouse lines
For thrombin generation experiments, FXII-/- and FXI-/- mice backcrossed for >10
generations140,141 and age-matched C57Bl/6 control mice (Charles River) were used.
For brain immunofluorescence and Western blot experiments, transgenic Tg6799
(Jackson Laboratory) and TgCRND8 (kindly provided by A. Chishti and D. Westaway,
University of Toronto, Canada) mouse models of AD were used. Tg6799 mice are double
transgenic for APP/Presenilin 1 and express five familial AD mutations: three in APP
(K670N/M671L, Swedish; I716V, Florida; V717I, London), and two in Presenilin1 (M146L,
L286V) under the mouse thy1 promoter. Tg6799 mice develop amyloid plaques at 2 months
of age and cognitive impairment by 4-5 months of age142. TgCRND8 mice express a double
mutant form of APP695 (K670N/M671L, Swedish; V717F, Indiana) under the human prion
protein promoter. TgCRND8 mice develop Aβ pathology and cognitive deficits as early as 3
months of age143. Non-transgenic littermates were used as controls. For analysis of plasma
contact system activation, Tg6799 mice and littermate controls were used. For Aβ42
injection experiments, 2 month old C57BL/6 mice (Jackson Laboratory) were used.
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2.18. Analysis of thrombin generation in human and mouse plasma
Real time thrombin generation in normal human plasma or FXII-deficient plasma (from
individuals genetically deficient in FXII; George King Biomedical) was measured by CAT as
described in 144. In some cases, plasma was pre-incubated for 30 min with an antibody
against FXIIa145 or active-site inhibited factor VII (ASIS; Novo Nordisk). Some reactions also
contained FXIa (3 pM). All samples were run in duplicate, and curves are representative of
at least 3 separate experiments run with plasma from different donors (for normal plasma).
Real time thrombin generation in FXII-/-, FXI-/-, and C57Bl/6 mouse plasma was measured
as described above, except a smaller amount of mouse PPP (40 µl) was used to obtain
stronger signal (as in 146).
2.19. Analysis of FXII, FXI, and prekallikrein activation in vitro
Chromogenic substrate assay: Assays were performed at 37°C in flat-bottom 96-well
polystyrene plates (Fisher Scientific) coated with 1% Polyethylene glycol 20,000 in HEPESbuffered saline (HBS) for 2 hrs. To measure FXII activation, Pefachrome FXIIa (H-D-CHAGly-Arg-pNA-2AcOH; Centerchem), final concentration 0.8 mM, was added to a mixture
containing 100 nM FXII (Haematologic Technologies) and 3 µM Aβ or vehicle. To measure
FXII-dependent prekallikrein activation, Pefachrome PK (H-D-But-CHA-Arg-pNA-2AcOH;
Centerchem), final concentration 0.8 mM, was added to a mixture containing 10 nM FXII, 10
nM plasma prekallikrein (Enzyme Research Laboratories) and 3 µM Aβ or vehicle. To
measure FXII-dependent FXI activation, Pefachrome FXIa (Z-Aad-Pro-Arg-pNA-AcOH;
Centerchem), final concentration 0.8 mM, was added to a mixture containing 5 nM FXII, 15
nM FXI (Haematologic Technologies), and 3 µM Aβ or vehicle. Enzyme activity was
detected as change in absorbance at 405 nm every 45 s using a Molecular Devices
Spectramax Plus 384 microplate reader.
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Western blot: Coagulation factor activation was analyzed in a purified protein system
and in human plasma. For FXII activation, FXII (200 nM) was incubated with Aβ42 (3 µM),
dextran sulfate 500 kDa (DS500; Sigma; 10 µg/ml), or vehicle for 30 min at 37°C. In some
experiments, prekallikrein (150 or 300 nM) and high molecular weight kininogen (HK; 300
nM) were added to the reaction. Reactions were stopped by adding reducing sample buffer
and heating for 5 min at 85°C. Immunoblots were probed with an antibody against FXII
(Hematologic Technologies). For FXI activation, FXII (200 nM), prekallikrein (150 nM), HK
(Molecular Innovations; 300 nM), and FXI (150 nM) were incubated with Aβ (3 µM), kaolin
(Fisher; 100 µg/ml), DS500 (10 µg/ml), or vehicle for 30 min at 37°C. Immunoblots were
probed with a monoclonal antibody against FXI (Haematologic Technologies). For
prekallikrein activation and HK cleavage, FXII (40 nM), prekallikrein (60 nM), and HK (60
nM) were incubated for 5 min at 37°C, and immunoblots were analyzed using a polyclonal
antibody against plasma prekallikrein (Affinity Biologicals) or a monoclonal antibody against
the light chain of HK (Abcam). For experiments in human plasma, plasma from healthy
volunteers or FXII-deficient plasma was diluted 1:10 in HBS and incubated with activators
for 1 hr at 37°C followed by Western blot analysis using the antibodies described above. For
FXII activation, plasma was incubated with Aβ42 (20 µM). For prekallikrein activation,
plasma was incubated with Aβ42 (20 µM) or kaolin (100 µg/ml). For HK cleavage, plasma
was incubated with various concentrations of Aβ and kaolin.
ELISA: Normal human plasma or FXII-deficient plasma were diluted 1:10 in HBS buffer
and incubated with Aβ42, Aβ42 Dutch (20 µM), kaolin (10 µg/ml), or vehicle at 37°C for 1 hr.
Reactions were transferred to a 96-well plate pre-coated with a monoclonal antibody against
FXI (3 µg/ml) overnight at 4°C, washed with PBS containing 0.05% Tween-20 (PBS-T), and
blocked with PBS containing 2% milk (blocking buffer) for 1 hr at RT. Reactions were
incubated in wells for 1 hr at RT, removed, and wells washed 3 x 5 min with PBS-T. A

25

polyclonal antibody against C1 inhibitor (Cedarlane) or alpha-1-antitrypsin (3 µg/ml; Thermo
Scientific) in blocking buffer was applied to the wells for 1 hr at RT. After washing, an HRPconjugated anti-goat antibody (Jackson; 1:2000) in blocking buffer was applied for 1 hr at
RT. The ELISA was developed with TMB peroxidase substrate (Thermo Scientific).
Absorbance was measured at 450 nm. All conditions were tested in triplicate.
2.20. Binding between Aβ and FXII, FXI
N-terminally biotinylated Aβ42 (200 nM) was incubated with FXII (200 nM) or FXI (100
nM) in PBS containing 0.01% NP-40 and protease inhibitor cocktail for 2 hrs at RT.
Pulldown assays were performed as described above and analyzed by Western blot using
monoclonal antibodies against FXII and FXI (Haematologic Technologies). For pulldown
assays in normal human plasma, plasma was diluted 1:5 in PBS containing 0.01% NP-40
and protease inhibitor cocktail and incubated with biotinylated Aβ42 (500 nM) or N-terminally
biotinylated amylin (500 nM; Anaspec) for 2 hrs at RT.
2.21. AD patient and control plasma samples
Experiments with human plasma were approved by the Rockefeller University
Institutional Review Board. Plasma from AD patients and ND controls was obtained from the
University of Kentucky Sanders-Brown Center on Aging (Group 1) and Washington
University Knight Alzheimer’s Disease Research Center (Group 2). For Group 1, blood from
18 AD and 11 ND individuals giving written, informed consent was drawn into heparinized
Vacutainer tubes with a 23 or 21 gauge needle. AD cases were defined by a clinical
diagnosis of AD as well as a postmortem Consortium to Establish A Registry for Alzheimer’s
Disease (CERAD) neuritic plaque score147 of B or C, corresponding to probable or definite
AD, respectively. ND cases had CERAD scores of 0 and no clinical diagnosis of AD. AD and
ND cases were gender and age-matched (Table 1). For Group 2, blood from 10 AD and 10
ND individuals was drawn using EDTA-coated syringes into polypropylene tubes containing

26

a final concentration of 5 mM EDTA. Plasma was prepared by centrifuging blood at 2000 x g
for 15 min, and flash frozen on dry ice prior to storage at -80°C. AD cases were defined by a
Clinical Dementia Rating (CDR) score14 of ≥0.5 and CSF Aβ42 levels <500 pg/ml, and ND
cases were defined by a CDR score of 0 and CSF Aβ42 levels >500 pg/ml (Table 2). CSF
Aβ42 cut-off values for AD vs. ND were based on correlations between CSF Aβ42 levels
and cortical amyloid load as assessed by positron emission tomography with Pittsburgh
Compound B148.
2.22. Analysis of contact system activation in AD patient plasma by Western blot
Plasma protein concentration was measured by BCA, and equal amounts of total protein
(20 µg) from each sample were analyzed by non-reducing or reducing Western blot with
monoclonal antibodies against FXII heavy chain (Haemotologic Technologies), HK light
chain (Abcam), FXI (Haematologic Technologies), C1 esterase inhibitor (Proteintech), and
transferrin (Abcam). Purified FXI, FXII, HK, C1 inhibitor (Athens Research and Technology),
and FXII-deficient plasma were loaded as positive controls for some experiments.
2.23. Measurement of kallikrein-like activity in human and mouse plasma
Plasma kallikrein-like activity was measured using the chromogenic substrate S-2302
(Chromogenix) based on the method described in 149 with some modifications. Plasma
(diluted 1:30) in 20 mM HEPES with 140 mM NaCl was mixed with S-2302 (0.67 mM final
concentration) in duplicate, and absorbance at 405 nm was read for 30 min at RT in a
Molecular Devices Spectramax 384 Plus spectrophotometer. The rate of substrate
conversion over time was calculated for each plasma sample by the data acquisition
software (Softmax 6.1; Molecular Devices), and expressed as a percentage of the rate
found for normal human or wild type mouse plasma fully activated with dextran sulfate 500
kDa. S-2302 can also be cleaved by FXIIa, FXIa, and plasmin. To determine whether S2302 cleavage was mediated by members of the contact activation pathway (kallikrein,
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FXIIa, or FXIa) or plasmin, plasmin activity in all samples was determined using a different
substrate (Pefachrome-5329, Pentapharm) and found not to differ between AD and ND
plasma (not shown).
2.24. Analysis of contact system activation in AD mouse plasma
All animal experiments were conducted in accordance with the guidelines of the US
National Institutes of Health Guide for the Care and Use of Laboratory Animals and with
approval from the Animal Care and Use Committee of The Rockefeller University. Tg6799
mice (n=7) or littermate control mice (WT; n=7) at 6 months of age were anesthetized with
atropine (500 mg/kg body weight) and avertin (0.04 mg/kg body weight) intraperitoneally.
Blood (100 µl) was collected via retro-orbital bleeding through gel-repel (Sigma) and
polybrene (Santa Cruz) coated capillaries into EDTA-coated tubes (BD) containing 5 mM
EDTA. Plasma was prepared by centrifugation (1500 x g for 15 min, twice), and stored in
polypropylene tubes containing 5 mM EDTA. Total protein concentration was determined by
BCA, and plasma from each mouse containing 20 µg total protein was analyzed by Western
blot using monoclonal antibodies against HK light chain (R&D) and transferrin (Abcam) in
that order. Blots were stripped between antibody incubations. Protein levels were quantified
by densitometric analysis.
2.25. Analysis of contact system activation in C57Bl/6 mice injected with Aβ
Aβ42, scrambled Aβ42, and amylin (Anaspec) were prepared as follows: peptides were
resuspended in a minimum amount of 1% NH4OH, then diluted to 1 mg/ml with PBS.
Peptide concentration was determined by BCA, and the state of aggregation was
determined by TEM. Aβ42, scrambled Aβ42, amylin, or vehicle (6 mg/kg body weight) were
administered via retro-orbital injection into 2 month-old C57BL/6 mice under anesthesia
using avertin and atropine as described above. After 6 hrs, blood was collected and
processed as described above. Western blot analysis was performed as described above.
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Levels of plasma Aβ42 were determined at 6 hrs post injection using an Aβ42-specific
ELISA kit (Life Technologies) according to the manufacturer’s instructions.
For analysis of the effect of different anticoagulants on ex-vivo contact activation, plasma
from non-injected WT mice was collected into EDTA or heparin tubes. Plasma was then
incubated with 20 µM Aβ42, scrambled Aβ42, amylin, or vehicle for 1 hr at 37°C, then
analyzed by Western blot as described above.
2.26. Analysis of brain tissue in AD patients and mouse models
Immunofluorescence: Mice were saline/heparin-perfused and brains were fixed in 4%
paraformaldehyde, cryoprotected in 30% sucrose, and frozen. Coronal sections (20 µm)
were blocked for 1 hr in PBS containing 0.25% Triton X-100 and 3% donkey serum
(Jackson Laboratory), incubated overnight at 4°C with anti-Aβ monoclonal antibody 6E10
(Covance) and FXII antibodies (Novus, HTI), followed by 1 hr incubation with Alexa-Fluor
secondary antibodies. Controls for secondary antibody non-specific binding were performed
by omitting primary antibodies. Sections were dehydrated and cover slips were applied with
Vectashield (Vector labs). Images were acquired using an inverted TCS SP8 laser scanning
confocal microscope (Leica DMI 6000) at the Rockefeller University’s Bio-Imaging Resource
Center and analyzed by ImageJ.
Western blot: Mouse (whole brain) and human (temporal pole) frozen tissue was
homogenized in 5 volumes (g/ml) of PBS containing 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, and protease inhibitor cocktail (Roche). The homogenates were centrifuged at
10,000 x g for 10 min at 4°C to yield a supernatant containing the soluble protein fraction.
Protein concentration was determined by BCA, and equal amounts were run on a 10%
polyacrylamide Criterion gel (Bio-Rad) followed by Western blot analysis with the following
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antibodies: murine HK (R&D Systems), tubulin (Abcam), human HK light chain (Abcam),
actin (Abcam), albumin (Thermo Scientific), hemoglobin (Abcam), and fibrinogen (Dako).
2.27. Antibodies

Table 2.1. List of antibodies used
Antigen

Actin
Albumin
Alpha-1-antitrypsin
C1 esterase inhibitor
C1 esterase inhibitor
Fibrinogen

Details
Mouse monoclonal
6E10
Mouse monoclonal
3D6
Chicken polyclonal
Goat polyclonal
Goat polyclonal
Goat polyclonal
Rabbit polyclonal
Rabbit polyclonal

FXI

Mouse monoclonal

FXII

Mouse monoclonal

FXII

Rabbit polyclonal

FXII

Sheep polyclonal

Aβ
Aβ

FXIIa
Hemoglobin
HK (human)
HK (mouse)
Plasminogen
Prekallikrein
Transferrin (human)
Transferrin (mouse)
Tubulin

Fully human
monoclonal 3F7
Rabbit monoclonal
Rabbit monoclonal to
light chain
Rat monoclonal to light
chain
Mouse monoclonal
10A1
Sheep polyclonal
Rabbit polyclonal
Rabbit polyclonal
Rat monoclonal
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Source

Applications

Covance

immunofluorescence

Elan

Western blot

Abcam
Thermo Scientific
MyBioSource
Cedarlane
Proteintech
Dako
Hameatologic
Technologies
Haematologic
Technologies
Novus
Haematologic
Technologies

Western blot
Western blot
ELISA
ELISA
Western blot
Western blot
ELISA, Western blot
Western blot
Immunofluorescence
Immunofluorescence

Larsson et al. 145

Inhibition studies

Abcam

Western blot

Abcam

Western blot

R&D

Western blot

Santa Cruz

ELISA

Affinity Biologicals
Abcam ab88165
Abcam ab82411
Abcam

Western blot
Western blot
Western blot
Western blot

2.28. Statistical analysis
Data are presented as column graphs with mean ± standard deviation (SD) or as vertical
scatter plots with medians and reported as means ± SD or medians in the text. Unless
otherwise indicated, comparisons between two groups were performed using the unpaired,
two-tailed t-test for parametric data or using the two-tailed Mann-Whitney test for nonparametric data. Comparisons between multiple groups were performed using KruskalWallis test followed by Dunn’s Multiple Comparison Test. For some experiments,
comparisons between groups were performed using 1 way ANOVA followed by Dunnett’s
Multiple Comparison Test for multiple groups with a single control. Two-way ANOVA with
Bonferroni post-test was used for comparisons between groups affected by two factors.
Correlation analysis was performed using Pearson’s correlation coefficient (r). P values
≤0.05 were considered significant (*), with values ≤0.01 designated (**), values ≤0.001
designated (***), and values ≤0.0001 designated (****) in figures. Statistical analyses were
performed using GraphPad Prism software, version 5.0f.
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CHAPTER 3. Mechanisms through which binding between Aβ42 and fibrinogen lead
to delayed fibrinolysis
3.1. Background
If the prothrombotic state observed in AD patients and mouse models contributes to AD
etiology, a better understanding of the mechanisms responsible for eliciting such a state is
crucial. One way to achieve a prothrombotic state is through impaired fibrin degradation
(fibrinolysis), which could prevent timely clearance of clots as well as increase the likelihood
that clots will form, since the thrombotic-fibrinolytic equilibrium during clot formation would
be disturbed. In this regard, the Strickland laboratory has shown that clots formed in the
presence of Aβ42 are structurally altered and more resistant to fibrinolysis than normal
clots59, and that fibrinogen, the main protein component of clots, can bind Aβ42 specifically
with a Kd of 26.3 ± 6.7 nM125. However, the mechanisms by which Aβ42-fibrin(ogen) binding
delays fibrin clot lysis have not been defined. To better understand how Aβ42 binding to
fibrin(ogen) can result in abnormal clot structure and to the decreased susceptibility of the
fibrin clot to fibrinolysis, I investigated the biochemical and structural details of the Aβ42fibrinogen interaction.
3.2. Biochemical details of the Aβ–fibrinogen interaction
Binding region for Aβ on fibrinogen. Fibrinogen is a 340 kDa glycoprotein composed of three
pairs of chains (α, β, and γ) organized into three structural regions, where two identical D
domains (fragment D) are joined by a central E domain (fragment E; Figure 3.1A). The
Strickland laboratory has previously shown that Aβ binds to fragment D of fibrinogen125. To
determine where within fragment D Aβ42 binds, I partially digested fibrinogen, generating
fibrinogen degradation products (FDPs). FDPs were pulled down using biotinylated Aβ42
and streptavidin, and the Aβ42-interacting peptides visualized using SDS-PAGE. The ~7
kDa Aβ-binding fragment (Figure 3.1B; Fragment 1) was analyzed by liquid
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chromatography-tandem mass spectrometry (LC-MS/MS) at the Rockefeller University’s
Proteomics Center, which mapped a portion of the ~7 kDa fragment to the C-terminal region
of the fibrinogen β-chain (β396-407). Consistent with this result, N-terminal sequencing of
the ~7 kDa fragment placed it within the C-terminal region of the β-chain (β366-370) (Figure
3.1C). The exact size of the fragment was determined using matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF) analysis, resulting in a mass corresponding to 49
amino acids, placing it between β366 and β414 (Figure 3.1C). These results indicate that
Aβ42 interacts with fibrinogen near the C-terminus of the fibrinogen β-chain, a region that
encompasses the functional domain called the b-hole (within the globular β-chain domain;
green in Figure 3.1A). The 49 amino acid peptide (β366-414) corresponding to the identified
fragment was synthesized at Rockefeller University’s Proteomics Resource Center, and its
ability to bind Aβ42 was confirmed by pulldown assay (Figure 3.1D) and by AlphaLISA
assay by Hyung Jin Ahn125, which demonstrated the ability of the 49-mer to inhibit Aβfibrinogen binding.

33

Figure 3.1. Localization of the Aβ42 binding site within fibrinogen fragment D. (A)
Fibrinogen is composed of two sets of α, β, and γ chains and organized into an E domain
flanked by two D domains (adapted from 150). (B) Biotinylated Aβ42 pulled down two
plasmin-generated fibrinogen degradation products (FDPs). Only the ~7 kDa fragment was
analyzed successfully. (C) The ~7 kDa fragment mapped to the C-terminus of the fibrinogen
beta chain by N-terminal sequencing and LC-MS/MS. MALDI-TOF identified 49 amino acids
in the fragment. (D) Silver-stained SDS-PAGE showing that biotinylated Aβ42 pulls down
the 49 amino acid fragment.
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Binding region for fibrinogen on Aβ. To determine which region of Aβ42 is responsible
for fibrinogen binding, fibrinogen and fragment D were pulled-down with biotinylated subregions of Aβ42. Fragments Aβ17-40 and Aβ22-41 had the strongest affinity for fragment D,
while Aβ1-16 had the least (Figure 3.2A, top), indicating that the C-terminal two thirds of the
molecule are involved in binding fragment D. Pulldown of fibrinogen with the same Aβ subregions yielded similar results, although more binding was detected to N-terminal Aβ
peptides (Figure 3.2A, bottom), suggesting that fibrinogen may have additional Aβ binding
sites outside of fragment D which may be mediated by N-terminal Aβ residues. This
interpretation is supported by data demonstrating an additional binding site for Aβ42 on the
fibrinogen α chain outside of fragment D (not shown, in collaboration with Hyung Jin Ahn).
Consistent with the binding site for fragment D on Aβ being located closer to its C-terminus,
incubation of biotinylated Aβ42 with fragment D in the presence of increasing concentrations
of Aβ17-42 resulted in a dose-dependent decrease in fragment D pulldown (Figure 3.2B).
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Figure 3.2. Localization of the fibrinogen binding site on Aβ42. Western blots showing
streptavidin pulldown assays probed with a polyclonal anti-fibrinogen antibody (Dako). (A)
Biotinylated Aβ fragments were used to pull down fibrinogen fragment D or fibrinogen. (B)
Aβ17-42 blocks the ability of biotinylated Aβ42 to pull down fragment D in a dose-dependent
manner.
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3.3. Structural details of the Aβ–fibrinogen interaction
Structural details of the Aβ42-fibrinogen interaction were investigated via X-ray
crystallography in collaboration with Hyung Jin Ahn and under the guidance of Deena Oren
of The Rockefeller University’s Structural Biology Resource Center. We sought to obtain a
crystal structure of the complex between Aβ42 and fragment D, due to results indicating that
fragment D is the major binding region for Aβ on fibrinogen and to the smaller size and ease
of manipulation of fragment D.
Our strategy was to soak Aβ42 into pre-formed fragment D crystals due to the large
solvent channels present in the fragment D structure. Fragment D crystals were obtained
using the method of 129 as detailed in Methods 2.7 (Figure 3.3A), and the ability of Aβ42 to
penetrate into the crystal lattice was tested by soaking fragment D crystals with fluorescently
labeled TAMRA (5-Carboxy-tetramethylrhodamine)-Aβ42. Non-specifically bound TAMRAAβ42 was removed by repeatedly washing the crystal until no decrease in fluorescence was
observed. Persistent fluorescence confirmed binding of Aβ42 within the crystals (Figure
3.3B). One challenge presented by soaking Aβ42 into fragment D crystals is the rapid
oligomerization of Aβ42, resulting in a wide range of species. To circumvent this problem,
we soaked crystals with the synthetic Aβ42 mutants I31P and G37D, which are less prone to
aggregation151,152, but can still bind fragment D (Figure 3.3C). Crystals were also soaked in
Aβ42, Hylite fluor 555-labeled Aβ42, or not soaked at all, and data sets were collected at the
National Synchrotron Light Source. The structure was solved by molecular replacement as
described in Methods 2.7. Soaking of Aβ42 did not damage fragment D crystals, since in
most cases the space groups and unit cell dimensions obtained were isomorphous with
dimensions found in unsoaked (native) crystals, and relatively well with published
dimensions for fragment D129 (Figure 3.3D). Analysis of electron density showed subtle
changes to the structure of fragment D soaked with all Aβ42 preparations compared to data
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obtained for a native (unsoaked) crystal, suggesting interaction between fragment D and
Aβ42. Specifically, a loop in the fragment D β-chain (β384-393), which forms part of the 49
amino acid Aβ42 binding region identified in Figure 3.1, was shifted away from the coiled
coil region in multiple crystals soaked with Aβ42 and 555-Aβ42 (Figure 3.3E; data shown
only for Aβ42-soaked crystal). This loop is shifted in a similar but not as dramatic a manner
in fragment D structures crystallized in the presence of b-hole binding peptides (as in PDB
1FZG153, among others; Figure 3.5F), suggesting that Aβ interacts with residues near the bhole. Peptides binding the b-hole also induced a flip in a nearby loop (β395-400), which was
not observed in our structure, suggesting that Aβ may not fit all the way in the b-hole as the
peptides do. We also observed patches of density unaccounted for by the fragment D
coordinates possibly corresponding to Aβ42. These patches of density were found in the
region of fragment D in special proximity to the 49 amino acid binding site on the β-chain the
binding site, but the density was not sufficient to conclusively place Aβ42 in that region (not
shown).

38

Figure 3.3. Altered fragment D structure in the presence of Aβ42. (A) Bright field (left)
and UV fluorescence (right) images of fragment D crystals, indicating crystals are
proteinacious. (B) Left: Bright field image of a fragment D crystal that had been subjected to
soaking in TAMRA-Aβ42 followed by extensive washing. Right: Persistent red fluorescence
after washing indicated that TAMRA-Aβ42 was binding within the crystal. (C) Western blot
analysis of a pulldown assay demonstrating that Aβ42 I31P and Aβ42 G37D bind to
fragment D. The blot was probed with antibodies against fibrinogen (top) and Aβ (bottom) to
demonstrate Aβ pulldown by biotinylated fragment D. (D) Unit cell dimensions of published,
non-soaked, and Aβ42-soaked fragment D crystals. Only Aβ42-soaked crystal unit cell
dimensions are shown, since data from other Aβ peptide soaks were similar. (E) Diagram of
fibrinogen indicating fragment D (FD; dashed line box) and where differences between nonsoaked and Aβ42-soaked fragment D crystals were found (solid line box). Superimposed
2Fo-Fc maps from non-soaked (pink; Rwork/Rfree = 0.24/0.33) and Aβ42-soaked (blue;
Rwork/Rfree = 0.28/0.39) fragment D crystals with coordinates of non-soaked crystals. (G)
Protein backbone diagram showing the shift of the β384-393 loop from native (1FZA) to bhole-peptide bound (1FZG) fragment D.
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3.4. Mechanism of fibrin formation and fibrinolysis
Upon exposure to thrombin, fibrinogen undergoes cleavage at the N-termini of its α and
β chains within the central E domain to reveal A- and B-knobs, respectively, yielding a fibrin
monomer. These knobs can interact with corresponding a- and b-holes in the D domains of
an adjacent fibrin(ogen) molecule to begin the process of fibrin polymerization (Figure 3.4,
blue panel). Fibrin monomers polymerize end-to-end into two-stranded protofibrils, which
then aggregate laterally into fibrils, which branch to form a gelationous fibrin network (Figure
3.4, green panel).
Fibrin clot degradation (fibrinolysis) is mediated by plasmin, a serine protease that
cleaves the fibrin network at specific sites, generating fibrin degradation products (Figure 3.4,
yellow panel). Plasmin is derived from the zymogen plasminogen by tissue plasminogen
activator (tPA) in the presence of fibrin, which itself enhances the rate of the reaction. One
fibrin site initially involved in plasminogen activation by tPA includes residues 148-160 on
the α-chain (Figure 3.4, pink panel; reviewed in 154). This site becomes exposed and
available for plasminogen binding after the conversion of fibrinogen to fibrin155, but could
remain hidden if clots are formed in the presence of Aβ, leading to delayed clot lysis. This
hypothesis is derived from our data indicating that Aβ binds the fibrinogen β-chain near the
b-hole (Figure 3.1 and 125), which is in close spatial proximity to residues 148-160 of the αchain (Figure 3.4, pink panel and 132). Another potential explanation for delayed clot lysis is
based on the relationship between fibrin structure and its susceptibility to fibrinolysis. Tighter
fibrin networks composed of thin fibers are degraded less efficiently by plasmin than those
composed of thick fibers138,156-158 because 1) there are more fibers to be cleaved157,159,
requiring plasmin to detach from and move between fibers more frequently160; and 2)
decreased network porosity of tighter fibrin networks results in impeded diffusion of
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fibrinolytic enzymes throughout the clot (reviewed in161). Potential effects of Aβ on fibrin fiber
thickness could thus be another mechanism of Aβ-mediated impaired fibrinolysis.
To determine the mechanism of Aβ42-mediated delay of fibrinolysis, I investigated the
effects of Aβ42 itself and of the Aβ2-influenced fibrin network on the activity and function of
the fibrinolytic factors tPA, plasminogen, and plasmin.
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Figure 3.4. Fibrin formation and fibrinolysis. Cleavage of fibrinopeptides A and B within
fibrinogen fragment E results in the formation of a fibrin monomer with exposed A- and Bknobs. These knobs interact with the a- and b-holes of fragment D domains on nearby fibrin
monomers to begin the process of fibrin polymerization (blue panel). Fibrin monomers
polymerize end-to-end into two-stranded protofibrils, which aggregate laterally into fibrils
(green panel). Fibrinolysis is initiated by binding of plasminogen and tPA to the forming fibrin.
The binding site for plasminogen on residues 148-160 of the α-chain is cryptic in fibrinogen
(blue panel) but becomes exposed in polymerizing fibrin (pink panel). Activation of bound
plasminogen to plasmin by tPA results in plasmin-mediated cleavage of the fibrin network
and the production of fibrin degradation products (yellow panel). Images adapted from
154

.
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162

,

3.5. Aβ42 present during or after clot formation results in delayed fibrinolysis
The effect on clot lysis of an Aβ42 preparation containing a mixture of monomeric,
oligomeric, and fibrillar species (Figure 3.5A, inset) was evaluated using two methods. In
one method, tPA was added to the clotting mixture at the start of clot formation to simulate
internal fibrinolysis, which is thought to approximate physiological conditions163. Lysis rates
were compared using half-lysis times, which were calculated as the time from when
maximum turbidity was achieved to when the clot reached half its maximum turbidity. The
effect of Aβ42 on clot lysis was tested over a wide range of tPA concentrations (Figure 3.5A;
only one tPA concentration shown for clarity), since tPA levels can increase dramatically
from their base levels in response to injury. A significant delay in lysis relative to control was
observed at all three tPA concentrations tested (Figure 3.5B), suggesting that the effect may
be relevant in chronic as well as acute injury states. Furthermore, the delay in lysis is Aβ
concentration-dependent, with concentrations from 500 nM to 3 µM producing significant
and increasing delays in lysis (Figure 3.5C,D). In a complementary method, pre-formed clots
made with or without Aβ42 were overlaid with tPA to initiate fibrinolysis, a system that is
more relevant to the pharmacological treatment of thrombosis163. In this system, half lysis
time was defined as the time from tPA overlay until the clot reached half its maximum
turbidity, and was significantly increased for Aβ42-containing clots (Figure 3.5E,F).
Aβ42 can adopt β-sheet structure, and it is possible that β-sheet structure alone was
responsible for delayed fibrinolysis. However, clots formed with the amyloid peptide amylin,
which had been aged and confirmed by TEM to contain fibrils (Figure 3.5G, inset), did not
exhibit delayed lysis (Figure 3.5G). Furthermore, a truncated Aβ peptide (Aβ1-28) had no
effect on clot lysis (Figure 3.5H). Thus, β-sheet structure alone is not enough to elicit
delayed clot lysis, and a specific interaction between Aβ42 and fibrin(ogen) is crucial for the
effect.
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Figure 3.5. Aβ42 delays fibrinolysis in dose-dependent manner. (A) Clot formation and
lysis were monitored by turbidity assay as described in methods. The presence of 3 µM
Aβ42 (labeled as Aβ on graphs) in the clotting solution resulted in decreased maximum
turbidity and delayed fibrinolysis (inset: TEM of Aβ42 used). (B) Time to half-lysis was
significantly higher for clots formed in the presence of Aβ42 compared to control clots for all
tPA concentrations tested. (C) Clots were formed with 0.5 µM, 1.5 µM, 3 µM Aβ42, or
vehicle and 1.5 nM tPA. (D) Time to half-lysis of Aβ42 clots was significantly delayed in a
dose-dependent manner. (E) Pre-formed clots prepared as described in methods were
overlaid with 50 nM tPA. (F) Time to half-lysis of Aβ42 clots was significantly higher than
control clots. (G) Clotting and lysis in the presence of 3 µM amylin confirmed by TEM to be
fibrillar (inset) did not differ from control. (H) Clotting and lysis in the presence of 3 µM Aβ128 did not differ from control.
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3.6. Aβ42 does not directly inhibit fibrinolytic enzyme activity
It is possible that Aβ42 interacts directly with fibrinolytic enzymes in solution and reduces
their activity. I assessed the effect of a range of Aβ42 concentrations on the activities of tPA
and plasmin. No effect of Aβ42 on tPA (Figure 3.6A) or plasmin (Figure 3.6B) activity was
observed. It has been shown that the conversion of plasminogen to plasmin by tPA is
enhanced in the presence of Aβ42, particularly for aggregated forms of Aβ42164-166. Since
Aβ42 preparations can vary dramatically, I wanted to exclude the possibility that our
preparation would decrease the conversion of plasminogen to plasmin. In agreement with
published results, I found that the generation of plasmin from plasminogen by tPA was
increased in the presence of Aβ42 in solution (Figure 3.6C). These data indicate that the
inhibitory effect of Aβ42 on clot lysis exists despite its ability to potentiate the generation of
plasmin in solution.
3.7. Aβ42-associated fibrin is a weaker enhancer of plasmin generation and a poorer
substrate for plasmin cleavage
Fibrin enhances the activation of plasminogen by tPA, and any changes introduced into
the fibrin network by Aβ42 could alter the efficiency of tPA/plasminogen interactions with
fibrin. To evaluate this possibility, I included the plasmin activity-monitoring chromogenic
substrate Pefa-5329 in clotting reactions, and the rate of plasmin generation was monitored
during clotting and lysis. Clots formed with Aβ2 showed delayed lysis and had reduced
plasmin activity compared to control clots (Figure 3.7A,B). Since the reduced activity in
Figure 3.7A is not due to sequestration of plasminogen by Aβ (not shown) or direct inhibition
of plasmin activity by Aβ42 (in solution – Figure 3.6B; in clot overlay – not shown) , it implies
a decrease in the rate of plasmin generation and may reflect Aβ-mediated disruption of the
interaction between fibrin and tPA/plasminogen. To determine whether the decrease in
plasmin generation is fibrin-related, I used streptokinase (SK) instead of tPA to activate
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plasminogen, since the rate of plasminogen activation by SK, unlike tPA, is not enhanced in
the presence of fibrin. Accordingly, there was no difference in plasmin generation between
Aβ42 and control when clots were lysed with SK and plasminogen (Figure 3.7C). Despite
similar rates of plasmin generation, the lysis of Aβ-influenced clots was still delayed with SKinitiated lysis (Figure 3.7C,D). This result could be due to the reduced capability of SKgenerated plasmin167 to bind or process fibrin fibers in Aβ-influenced clots versus control
clots.
To test this possibility, I initiated clot lysis using pre-formed plasmin in order to bypass
the plasminogen activation step. In agreement with the SK/plasminogen result, we observed
an increase in half-lysis time of Aβ42-influenced clots compared to control clots (Figure 3.8,
A and B). Plasmin interacts with fibrin through several binding domains and a catalytic
domain160. The serine protease trypsin is also able to dissolve fibrin clots160, but in contrast
to plasmin, it operates entirely through its catalytic domain. When pre-formed clots were
overlaid with trypsin, no delay of lysis of Aβ42-influenced clots was observed (Figure 3.8, C
and D), suggesting that Aβ interferes with plasmin’s access to its binding site and not its
cleavage site on fibrin.
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Figure 3.6. Aβ42 does not directly inhibit fibrinolytic enzyme activity. Aβ42 at 1 µM, 5
µM, and 10 µM or vehicle was combined with (A) tPA and the chromogenic substrate S2288 to monitor tPA activity; (B) plasmin and the chromogenic substrate Pefa-5329 to
monitor plasmin activity; or (C) tPA, plasminogen (plg), and Pefa-5329 to monitor plasmin
generation from plasminogen. Representative results from ≥3 separate experiments.
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Figure 3.7. Plasmin generation by tPA, but not streptokinase, is decreased in Aβ42influenced clots. (A) Fibrinogen, plasminogen, tPA, thrombin, CaCl2, and Pefa-5329 or
vehicle were mixed with or without 3 µM Aβ42. Absorbance was measured at 350 nm to
follow clot formation and lysis and at 405 nm to monitor plasmin activity. Curves of A405
without Pefa-5329 were subtracted from Pefa-5329 A405 curves to control for A405 arising
from clot turbidity and not plasmin activity. (B) Half-lysis of tPA/plasminogen-lysed clots was
delayed in the presence of Aβ compared to control (p = 0.011). (C) Same as (A), except
streptokinase (SK) was substituted for tPA. (D) Half-lysis of SK/plasminogen-lysed clots was
delayed in the presence of Aβ42 compared to control (p = 0.005).
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Figure 3.8. Aβ42-influenced clots are resistant to lysis by plasmin but not trypsin. (A)
Pre-formed clots prepared as described in methods with or without 5 µM Aβ42 were overlaid
with 250 nM plasmin. (B) Half-lysis was significantly slower in clots containing Aβ42 (p =
0.0001). (C) Pre-formed clots as in (A) were overlaid with 1 µM trypsin. (D) There was no
significant difference between half-lysis times of control and Aβ42 clots (p = 0.12).
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3.8. Aβ42 is incorporated into fibrin fibers throughout the clot network
The Strickland laboratory has previously shown that Aβ42-influenced clots are
characterized by irregular clusters punctuating the fibrin network, and Congo Red staining
(which stains amyloid fibrils) suggested that Aβ42 was confined to these clusters59. My
hypothesis that Aβ42 interferes with plasmin(ogen)’s access to fibrin throughout the fibrin
network requires its regular distribution along fibrin strands. This prompted me to more
closely analyze Aβ42 localization within clots. Tracer amounts of Alexa Fluor-488-labeled
fibrinogen (fibrinogen-488) were used to visualize the fibrin network, and HiLyte Fluor-555labeled Aβ42 (Aβ42-555), was used to visualize Aβ42. In agreement with previous results,
clots formed in the absence of Aβ42 showed a regular fibrin network (Figure 3.9A), while
clots formed in the presence of Aβ42 contained irregular clusters (Figure 3.9C, E,I). Aβ42555 labeling of irregular clusters (Figure 3.9F,H; arrowhead) confirmed our previous
conclusion that Aβ42 binds to fibrin aggregates. However, the uniform labeling of normal
fibrin fibrils by Aβ42 (Figure 3.9F,H) showed that it is also distributed throughout the fibrin
lattice. The striking co-localization between fibrin and Aβ42 is not due to the detection of
fibrinogen-488 fluorescence in the 555 channel, since clots formed without Aβ42-555
produced no signal in the 555 channel (Figure 3.9, B and D). Furthermore, omitting labeled
fibrinogen, but not labeled Aβ42, reproduced the Aβ42-covered fibrin lattice (Figure 3.9, G
and H). Replacing 555-Aβ42 with 555-Aβ(1-9), which does not cause delayed fibrinolysis
(not shown), eliminated the co-localization (Figure 3.9, I and J), confirming that the labeling
reflects specific Aβ-fibrin(ogen) binding and is not a result of nonspecific trapping of the 555labeled peptides in the forming fibrin network. Clots made without unlabeled Aβ42 but still
containing 555-Aβ(1-9) did not have co-localization between fibrin and Aβ(1-9) (not shown),
precluding the possibility that unlabeled Aβ42 blocks access of 555-Aβ(1-9) to fibrin. The
specific Aβ42-fibrin co-localization found in these experiments, together with the previously
described spatial proximity of Aβ42 and plasminogen binding sites on fibrin(ogen)125,132,
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suggested that Aβ42 could block plasmin(ogen) from accessing its binding sites on fibrin.
However, another potential mechanism became apparent: Aβ42-influenced fibrin is
composed of thinner fibers arranged in a tighter network than control fibrin (Figure 3.9, A vs.
C), which could make it more resistant to fibrinolysis138,156-158.
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Figure 3.9. Aβ42 binds to fibrin fibrils and alters fibrin structure. Fibrin clots were
formed with or without Aβ42 as described in methods to determine the location of Aβ42
binding. (Top row) Fibrin visualized with Alexa-488 labeled fibrinogen (green); (Bottom row)
Aβ visualized with HiLyte Fluor 555-labeled Aβ42 (red); (A,B) Control clot. (C,D) Clot with
only unlabeled Aβ42 shows that fibrin fibers and irregular clusters do not produce signal in
the red channel. (E,F) Clot formed with unlabeled Aβ42 and HiLyte Fluor 555 labeled Aβ42
shows co-localization between Aβ42 and fibrin fibers as well as Aβ42 and irregular clusters
(arrowhead). (G,H). Clot formed without Alexa-488 labeled fibrinogen but with both
unlabeled and labeled Aβ42 shows Aβ42 signal in the fibrin fiber pattern, confirming that
Aβ42 signal is not Alexa-488 signal detected in the red channel. (I,J) Clot formed with
unlabeled Aβ42 and HiLyte Fluor 555-labeled Aβ(1-9) does not have Aβ(1-9) signal along
fibrin fibers or in aggregates, indicating that the Aβ42 signal represents specific Aβ42fibrin(ogen) binding and not fluorophore entrapment. Images are representative of ≥3
experiments.
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3.9. Binding of plasminogen to fibrin and plasmin generation are decreased in the
presence of Aβ42
I next tested if Aβ42 binding to fibrin affected the ability of plasminogen to bind to fibrin
using two complementary approaches: confocal microscopy of clots formed with FITC
labeled plasminogen and ELISA with an antibody against plasminogen. Confocal
microscopy of clots formed with FITC-plasminogen showed plasminogen binding as
fluorescence in the pattern of the fibrin network to which it was bound (Figure 3.10A).
Fluorescence was decreased in clots containing Aβ42 (Figure 3.10B), suggesting that less
plasminogen was bound to the fibrin network (plasminogen does not bind to Aβ; not shown).
The amount of plasminogen binding was quantified as total fluorescence intensity per slice,
since fluorescence intensity is greater for FITC-labeled proteins bound to their target than
for FITC-labeled proteins in solution168. Total fluorescence was significantly lower for Aβ42containing clots (Figure 3.10C). These results demonstrate that Aβ42-modified fibrin binds
less plasminogen, but they do not prove that Aβ is blocking plasminogen’s access to fibrin,
since changes in fibrin fiber thickness may be an alternative explanation. To avoid the
possible modification of fibrin fibers by Aβ42 during fibrin formation, I used an immobilized
fibrin monolayer overlaid with Aβ or vehicle as a surface for plasminogen binding. Excluding
Aβ42 from fibrin polymerization eliminates the influence of Aβ42 on fibrin thickness, and also
changes the binding target for Aβ42 from fibrinogen to fibrin. The binding affinity of Aβ42 for
pre-formed fibrin may be different (and possibly lower) than for fibrinogen due to
conformational changes near the Aβ binding site on fibrinogen that accompany the
fibrinogen-fibrin transition. Nonetheless, Aβ42 overlay of fibrin monolayers decreased the
amount of plasminogen bound to fibrin (Figure 3.10D), suggesting that Aβ42 can inhibit
plasminogen binding to fibrin by impeding its access to fibrin independently of fibrin fiber
thickness.
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Figure 3.10. Aβ42 inhibits plasminogen binding to fibrin and plasmin generation.
Fibrin clots were formed with FITC-plasminogen as described in methods, and 5 µm zstacks composed of 11 sections were acquired and projected two-dimensionally for control
(A) and Aβ42-containing (B) clots. Images of 15 random sections from 3 separate clots were
also acquired and used for quantification (insets show representative single sections). (A)
Control clots formed with FITC-plasminogen show plasminogen fluorescence in the pattern
of the fibrin network. (B) Clots formed with Aβ42 have less FITC-plasminogen fluorescence.
(C) Fluorescence intensity relative to maximum intensity recorded was significantly lower
(p=0.02) for Aβ42-containing clots. (D) Plasminogen binding to fibrin monolayers exposed to
2 µM Aβ42 or vehicle was measured by ELISA and normalized to samples not containing
plasminogen. Plasminogen binding was decreased in the presence of Aβ42 (p = 0.04). (E)
Plasmin generation was measured by overlaying tPA, plasminogen, and chromogenic
substrate Pefa-5329 on fibrin monolayers exposed to 2 µM Aβ42 or vehicle and recording
absorbance at 405 nm. Plasmin generation on fibrin monolayers exposed to Aβ42 was
attenuated.
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To test whether the decrease in plasminogen binding translates to decreased plasmin
generation, fibrin monolayers were exposed to Aβ42 or vehicle, and the rate of plasminogen
activation by tPA was measured using chromogenic substrate Pefa-5329. Plasmin activity
was decreased in fibrin monolayers that had been exposed to Aβ42 (Figure 3.10E). The
activation of plasminogen by tPA was fibrin-dependent, since identical reactions in wells that
did not contain fibrin monolayers produced negligible amounts of plasmin (not shown). This
confirms that fibrin in the presence of Aβ is a weaker enhancer of plasminogen activation by
tPA (as in Figure 3.7), but without the differences in clot structure as a confounding factor.
3.10. Aβ42 overlaid onto pre-formed clots delays fibrinolysis
I next tested whether Aβ42 can delay fibrinolysis independently of its effect on clot
structure. Clots prepared without Aβ42, and therefore having normal structure, were overlaid
with a solution containing Aβ or vehicle for 1 hour, after which the solutions were removed
and the clot surfaces washed. The clots were then overlaid with a tPA solution to initiate
fibrinolysis. Aβ42 overlay significantly delayed half-lysis of clots compared to control (Figure
3.11A,B), indicating that Aβ-mediated alterations in clot structure are not necessary for
Aβ42-mediated clot lysis delay.
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Figure 3.11. Pre-formed clots overlaid with Aβ42 are resistant to lysis. (A) Pre-formed
clots (prepared as described in methods) containing no Aβ were overlaid with 5 µM Aβ42
(dashed line) or control buffer (solid line) for 1 hr, the overlays removed, and the clot
surfaces washed. All clots were then overlaid with 10 nM tPA to initiate lysis. (B) Half lysis of
clots that had been overlaid with Aβ was significantly delayed compared to control clots (p =
0.012). (C-H) Confocal microscopy of clots using Alexa Fluor-488 labeled fibrinogen and
HiLyte Fluor-555 labeled Aβ. (C,D) Normal clot overlaid with buffer. (E,F) Normal clot
overlaid with 555-Aβ42 (3 µM) for 1 hr contained fibrin-bound Aβ42 (G,H). Normal clot
overlaid with 555-Aβ(1-9) (3 µM) for 1 hr did not show specific co-localization between fibrin
and Aβ(1-9). Images are representative of ≥3 experiments.
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I examined if the delay in lysis provoked by overlaid Aβ42 results from its ability to
penetrate the clot and bind to fibrin after clot formation. Clots formed without Aβ42 were
overlaid with Aβ42-555 and incubated for 1 hour. After removal of the overlay and washing,
the interior of the clots was visualized. No structural alterations of the Aβ-overlaid fibrin
network were found (Figure 3.11C,E). However, Aβ42-555 labeling of the fibrin fibers was
observed (Figure 3.11F), indicating that Aβ had penetrated the clot and accumulated on the
fibrin lattice. Overlays with Aβ(1-9)-555 did not lead to specific 555-labeling of fibrin, but
produced diffuse fluorescence corresponding to non-specific penetration of Aβ(1-9)-555 into
the clot (Figure 3.11H). The delay in lysis in these structurally normal clots could thus result
from Aβ-mediated blockage of plasmin(ogen)’s access to fibrin (Figure 3.10).
Taken together, these results show that generation of plasmin is slowed, and that
plasmin-mediated degradation of clots is attenuated in clots formed with Aβ42. This occurs
through Aβ42-mediated hindrance of plasmin(ogen)’s access to fibrin and from Aβ-induced
tightening of the fibrin network, and not through the direct effect of Aβ42 on fibrinolytic
enzyme activity. Inhibiting the binding between Aβ42 and fibrinogen could therefore
normalize fibrin clot lysis and possibly reduce the prothrombotic phenotype observed in AD
patients and mouse models.
3.11. Aβ42 aggregation state: effects on clot structure fibrinolysis
Aβ42 aggregates into oligomers, protofibrils, and fibrils, a process that may be
accelerated in the presence of fibrin(ogen)125. To determine whether the aggregation state of
Aβ42 modulates its effect on fibrin clot structure and fibrinolysis, preparations of Aβ42 with
varying potential for aggregation were used. Aβ42 I31P is unable to form aggregates with
beta-sheet structure152, a characteristic of Aβ fibrils. Incubation of Aβ42 I31P for 24 hours at
37oC resulted in much less aggregated material by TEM compared to Aβ42 (Figure 3.12A,B).
Aβ I31P was able to bind fibrinogen, as demonstrated by pulldown assay using biotinylated
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fibrinogen FragD (Figure 3.3A) and via ELISA to fibrin monolayer (not shown). Unlike fibrin
clots formed in the presence of Aβ42, clots formed in the presence of Aβ42 I31P were not
characterized by clumps and a thinner network of fibers or differ in any other way from clots
formed with vehicle (Figure 3.12D-F). Furthermore, clots formed in the presence of Aβ42
I31P had similar susceptibility to lysis as clots formed with vehicle (Figure 3.12, G and H),
suggesting that Aβ42 aggregates/structures need to attain a certain size threshold in order
for their binding to fibrin(ogen) to affect clot structure and susceptibility to lysis.
Unlike Aβ42, Aβ42 labeled with the fluorophore 555 Hylite Fluor (Aβ42-555) forms
oligomers and protofibrils but does not assemble into fibrils following incubation (Figure
3.12A,C). Aβ42-555 is able to bind to fibrin(ogen), as shown by the colocalization of the
peptide with the fibrin network (Figure 3.12J) and pulldown assay (not shown). Clots formed
in the presence of Aβ42-555 have a thinner network of fibrin than control clots but lack the
clumps seen in clots formed with Aβ42 (Figure 3.12H,I). Furthermore, Aβ42-555-influenced
clots are more resistant to fibrinolysis than control clots, which is not a function of the
fluorophore, since Aβ(1-9)-555 had no effect on clot lysis (Figure 3.12K).
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Figure 3.12. Aβ42 aggregation state differentially affects fibrin structure and lysis. (A)
TEM of Aβ42 showing oligomers, protofibrils, and fibrils. (B) TEM of Aβ42 I31P mutant
showing a lack of oligomers and fibrils. Monomers are too small to be visualized by EM. (C)
TEM of 555-Aβ42 showing oligomers but no fibrils. (D-F) Fibrin clots prepared in the
presence of vehicle (D), Aβ42 (E), or Aβ42 I31P (F). Fibrin fibers are shown in green. (G)
Fibrinolysis is not delayed in the presence of Aβ42 I31P. (H-J) Fibrin clots prepared in the
presence of vehicle (H) or 555-Aβ42 (I,J). Fibrin (green) is shown in H and I, while 555-Aβ42
(red) is shown in J. (K) Fibrinolysis is delayed in the presence of Aβ42-555 but not Aβ(1-9)555, indicating that fibrinolysis is not inhibited by the fluorophore conjugated to Aβ42.
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CHAPTER 4. Aβ42 is prothrombotic via activation of the FXII-driven intrinsic
coagulation pathway
4.1. Aβ42 promotes thrombin generation in plasma
A prothrombotic state may be achieved not only by decreased fibrinolysis, as described
in Chapter 3, but also by over-activation of the coagulation cascade. To test if Aβ42 could
promote coagulation, I quantified thrombin generation in human plasma using the Calibrated
Automated Thrombogram method (CAT)144 in the presence of oligomeric Aβ42, a toxic
assembly that correlates with disease severity169. The oligomeric composition of my Aβ42
preparation (Methods 2.15) was confirmed by electron microscopy (Figure 4.1A). In the
absence of exogenous activators, a small thrombin burst is detectable after a long lag period
(Vehicle, Figure 4.1B-D). Addition of Aβ42 to platelet rich plasma promoted thrombin
generation in a dose-dependent manner, as indicated by a shortening of the lag time to
thrombin burst and an increase in peak height (maximum thrombin formed) (Figure 4.1B). A
similar prothrombotic effect was observed in platelet poor plasma (Figure 4.1C), indicating
that platelets are not required. However, Aβ42 had no effect in microparticle- and exosomefree plasma prepared by ultracentrifugation (Figure 4.1D). Supplementing ultracentrifuged
plasma with phospholipids restored Aβ42’s ability to trigger thrombin generation (Figure
4.1D), indicating that the presence of phospholipid surfaces (found on platelets,
microparticles, or exosomes) is required for Aβ42-mediated thrombin generation. The
prothrombotic effect is specific to Aβ42, since amylin, another amyloid-forming peptide,
failed to induce thrombin generation (Figure 4.1E).
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Figure 4.1. Aβ42 triggers thrombin generation in human plasma. (A) Representative
TEM image of Aβ42 oligomers used. (B-E) Real-time thrombin generation was measured by
CAT. (B) Platelet rich plasma (PRP) was incubated with Aβ42 at concentrations indicated or
kaolin (a known activator of thrombin generation). Lag time to thrombin generation was
decreased and thrombin peak was increased in the presence of Aβ42 in a dose-dependent
manner. (C) As in (B), except platelet poor plasma (PPP) was used. (D) Aβ42 had no effect
in plasma lacking platelets microparticles, and exosomes (labeled as Microparticle Free
Plasma). Addition of phospholipids (PL; 4 µM) restored Aβ42’s ability to trigger thrombin
generation. (E) Lag time to thrombin generation was decreased and maximum peak height
was increased in PPP with Aβ42 but not amylin. All experiments were performed in
duplicate, and averaged curves are presented.
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4.2. Aβ42-mediated thrombin generation is FXII-dependent
Thrombin is generated through the activation of either the intrinsic (FXII-driven) or
extrinsic (tissue factor; TF-driven) pathways of coagulation (Figure 4.2A). To determine
which pathway is activated by Aβ42, CAT experiments were performed in the presence of
either a FXIIa function blocking antibody145 (to block the intrinsic pathway), or with active
site-inhibited factor VII (ASIS; to block the extrinsic pathway). The FXIIa antibody abolished
Aβ42-induced thrombin generation (Figure 4.2B), whereas ASIS had no effect (Figure 4.2C),
suggesting that Aβ42 is prothrombotic via the FXIIa-driven intrinsic coagulation pathway.
The specificity of the FXIIa antibody to block FXIIa-mediated thrombin generation was
confirmed by showing that it blocked thrombin generation initiated by kaolin, a known
activator of FXII, but did not interfere with tissue factor (TF)-initiated thrombin generation. As
expected, ASIS inhibited TF-initiated thrombin generation (not shown).
To further examine the role of FXII in Aβ42-mediated thrombin generation, I analyzed
the effect of Aβ42 in plasma obtained from an individual deficient in FXII, having no
detectable plasma FXII antigen (Figure 4.2D inset). Aβ42 failed to trigger thrombin
generation in FXII-deficient human plasma (Figure 4.2D, dashed curves). To examine the
role of Aβ42 in a system where FXII is completely absent, I tested plasma from mice that do
not express any FXII (FXII-/-). While Aβ42 promoted thrombin generation in WT mouse
plasma, no effect was seen in FXII-/- mouse plasma (Figure 4.2E), corroborating results
obtained from plasma in which FXIIa was blocked by antibody (Figure 4.2B) and from FXIIdeficient human plasma (Figure 4.2D).
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Figure 4.2. Aβ42 promotes thrombin generation in a FXII-dependent manner. (A)
Intrinsic and extrinsic pathways of coagulation. (B-E) Real-time thrombin generation was
analyzed by CAT. (B) Aβ42-induced thrombin generation was blocked by a monoclonal
antibody against FXIIa (4 µM), but not by IgG. (C) Aβ42’s enhancement of thrombin
generation was not affected by the extrinsic coagulation pathway inhibitor ASIS (60 nM). (D)
Thrombin generation was not enhanced in human plasma from a FXII-deficient individual in
the presence of Aβ42. Deficiency of FXII in this plasma was confirmed by Western blot (WB;
inset). Aβ42 had no effect when thrombin generation was triggered by 3 pM FXIa. (E)
Thrombin generation was enhanced in WT mouse plasma but not FXII-/- mouse plasma in
the presence of Aβ42. Mouse plasma contained 240 nM ASIS to block TF-mediated
thrombin generation stemming from TF contamination during blood draw. ASIS does not
affect Aβ42-mediated enhancement of thrombin generation (Figure 4.2C). All experiments
were performed in duplicate, and averaged curves are presented.
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Since FXII-deficient or -neutralized plasmas have normal levels of FXI, FIX, FX, FVII,
and prothrombin, the results also indicate that thrombin generation is not driven through
direct activation of any of these factors by Aβ42. However, it is possible that Aβ42 may
potentiate these factors when they are in the activated state, low levels of which may be
induced by minute FXII activation triggered by contact with the well surface or during
sampling and storage (e.g. the background thrombin signal in Figure 4.1B-D). To address
this possibility, thrombin generation in FXII-deficient human plasma was measured following
addition of low levels of FXIa, which can activate the remaining members of the coagulation
cascade (Figure 4.2A). Aβ42 had no effect on thrombin generation in plasma activated with
FXIa (Figure 4.2D, solid curves), indicating that it does not enhance the activity of FXIa or
any downstream factors. Furthermore, Aβ42 had no effect on thrombin generation in plasma
from mice that have normal levels of FXII but do not express FXI (not shown), confirming
that the pathway enhanced by Aβ42 involves FXIIa-mediated activation of FXI and not
FXIIa-mediated activation of another substrate.
4.3. Aβ42 oligomers trigger FXII-dependent FXI activation in vitro
FXII undergoes autoactivation on negatively charged surfaces to generate FXIIa. Since
autoactivation of FXII has only been shown with fibrillar Aβ and in the presence of ZnCl2121, I
first determined that Aβ42 oligomers can bind FXII (Figure 4.3A, first panel) and directly
induce FXII autoactivation (Figure 4.3B). Physiologically, contact system activation takes
place in the presence of prekallikrein, which is activated by FXIIa to kallikrein, which in turn
activates additional FXII, amplifying the reaction (feedback activation; Figure 1.2). Aβ42
dose-dependently promoted FXII activation in the presence of prekallikrein (Figure 4.3C), as
seen through the reduction of FXII zymogen levels (80 kDa) and the appearance of the
heavy chain fragment of FXIIa (52 kDa).
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The activation of FXI by FXIIa requires co-localization of the two factors on the activating
surface. A pulldown assay revealed that Aβ42 binds both FXI and FXII (Figure 4.3A),
indicating that Aβ42 oligomers are a surface capable of co-localizing FXII and FXI, thereby
facilitating FXIIa-mediated FXI activation. Indeed, Aβ42 led to robust FXIIa-dependent FXIa
generation compared to vehicle in the absence (Figure 4.3D) and presence (Figure 4.3E) of
prekallikrein, indicating that FXII activated by Aβ42 is capable of cleaving its substrate FXI.
Interestingly, the relationship between the concentration of Aβ42 oligomers and the level of
FXII-dependent FXI activation was not linear. FXI activation peaked at ~500 nM Aβ42, with
further increases to Aβ42 concentration resulting in diminished FXI activation (Figure 4.3F).
This behavior is consistent with a template-like mechanism for this process, where there is
an optimal concentration of Aβ42 that allows FXII and FXI to bind the same Aβ42 molecule.
Too much Aβ42 separates FXII and FXI to different Aβ42 molecules, resulting in less
intermolecular interaction and decreased activation.
Previously, FXIIa-dependent FXI activation and procoagulant effects were not detected
when Aβ42 was tested as an activator122. The main difference between our experiments is
that Maas et al. used “amorphous aggregates” of Aβ42 with the Dutch mutation (E22Q)
instead of the oligomeric Aβ42 tested here. This discrepancy prompted me to analyze the
ability of Aβ42 in different states of aggregation as well as other Aβ variants to trigger FXIIdependent FXI activation. My results demonstrate that Aβ42 oligomers had a much greater
ability to trigger FXII-dependent FXI activation compared to freshly dissolved Aβ42 and
Aβ40 (Figure 4.3G,H). No FXI activity was detected in the presence of Aβ42 fibrils (Figure
4.3G). However, even when the most active (oligomeric) form of Aβ42 Dutch was tested, it
was substantially less potent than oligomeric Aβ42 in stimulating FXII-dependent FXI
activation (Figure 4.3I), indicating that the discrepancy between our results is a function of
the use of Aβ42 Dutch in the Maas et al. study.
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Figure 4.3. Aβ42 promotes FXII-dependent FXI activation in vitro. (A) Western blot
showing results of pulldown assay with biotinylated Aβ42 oligomers and purified FXII (left
panel) or FXI (right panel). Western blots were probed with anti-FXII and FXI antibodies,
respectively. (B) Aβ42 triggered autoactivation of FXII by chromogenic substrate assay. (C)
In the presence of both FXII and prekallikrein, Aβ42 dose-dependently promoted activation
of FXII as seen through the reduction of FXII zymogen level at 80 kDa and appearance of
the FXIIa heavy chain at 52 kDa. Dextran sulfate 500 kDa (DS500) and kaolin were used as
positive controls. (D) Aβ42 triggered FXII-dependent FXIa generation by chromogenic
substrate assay. The signal was not due to non-specific cleavage of chromogenic substrate
by FXIIa, or by autoactivation of FXI, as seen in controls where FXII or FXI were omitted. (E)
FXI activation can be seen through the appearance of the 50 kDa FXIa heavy chain band
following incubation of FXII, FXI, prekallikrein (PPK), and HK with Aβ42 or kaolin. (F) FXIIdependent FXI activation was analyzed with various concentrations of Aβ42 oligomers by
chromogenic substrate assay and absorbance after 2 hours analyzed. Significance is with
respect to vehicle (0 nM Aβ42). (G) Aβ42 oligomers were more potent in promoting FXIIdependent FXI activation than freshly dissolved Aβ42. Aβ42 fibrils had no effect. (H) Aβ42
oligomers were more potent than Aβ40 oligomers in promoting FXII-dependent FXI
activation. (I) Aβ42 oligomers (TEM image, top inset) promoted FXII-dependent FXI
activation much more strongly than Aβ42 Dutch oligomers (TEM image, bottom inset).
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4.4. Aβ42 oligomers trigger FXII-dependent FXI activation in plasma
To investigate the relevance of FXII-mediated FXI activation by Aβ42 to a more complex
environment, I examined this process in human plasma. Biotinylated Aβ42, but not
biotinylated amylin, was able to bind FXII in plasma as shown by pulldown assay (Figure
4.4A), demonstrating that the Aβ42-FXII interaction is specific and occurs in the presence of
plasma proteins. This interaction leads to FXII activation, since plasma incubated with Aβ42
had decreased FXII zymogen and increased FXIIa heavy chain compared to incubation with
vehicle (Figure 4.4B). While Western blotting cannot sensitively detect FXI activation,
plasma FXIa can be measured by quantifying FXIa-inhibitor complex formation, since FXIa
generated in plasma is rapidly bound by inhibitors170. Incubation of plasma with Aβ42 but not
Aβ42 Dutch resulted in significantly increased levels FXIa-C1 inhibitor (C1inh) complex than
when plasma was incubated with vehicle (Figure 4.4C; p <0.001). The activation of FXI by
Aβ42 was FXII-dependent, since incubation of FXII-deficient plasma with Aβ42 did not result
in increased FXIa-C1inh complex formation. Because multiple inhibitors neutralize FXIa in
plasma, I tested whether FXIa generated in plasma following Aβ42-mediated activation of
FXII is bound by other inhibitors in addition to C1inh. The level of FXIa-α1 antitrypsin (α1AT)
complex in plasma following activation with Aβ42 was also increased relative to vehicle
(Figure 4.4D; p<0.0001).
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Figure 4.4. Aβ42 promotes FXII-dependent FXI activation in plasma. (A) Western blot
demonstrating that biotinylated Aβ42 oligomers bind FXII in human plasma. (B) Aβ42
oligomers incubated with human plasma lead to FXII activation. (C) ELISA measuring FXIaC1inh complex formation in normal and FXII-deficient human plasma. Oligomers of Aβ42
but not Aβ42 Dutch promoted the formation of more FXIa-C1inh than vehicle (p <0.001) (D)
ELISA measuring FXIa-α1AT complex formation in normal human plasma. Aβ42 oligomers
resulted in increased complex formation compared to vehicle (p <0.0001). Results are
presented as mean ± SD of experiments performed in triplicate.
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4.5. Levels of FXI zymogen and C1inh are decreased in AD patient plasma
In vivo, increased activation of plasma FXI can be detected as decreased plasma FXI
zymogen levels, often observed in disease states accompanied by FXI activation171-173.
Decreased plasma FXI zymogen levels could reflect continuous consumption of FXI due to
its activation and clearance. Levels of FXI zymogen normalized to transferrin loading control,
plasma levels of which are not altered in AD174, were analyzed by Western blot in two sets of
AD patient and non-demented control (ND) plasmas obtained from two AD tissue banks
(see Methods 2.21). Ten AD and 10 ND cases in Group 1 were age-, gender-, and ApoE
genotype-matched, while 10 AD and 10 ND cases in Group 2 were age-matched. AD
plasma had decreased levels of FXI zymogen compared to ND plasma in both Group 1
(0.43 ± 0.07 vs. 0.69 ± 0.20, p = 0.008; Figure 4.5A,B) and Group 2 (0.85 ± 0.25 vs. 1.44 ±
0.28, p = 0.0003, p <0.0001; Figure 4.5D,E). If AD plasma FXI levels are decreased due to
its activation and clearance, levels of its main inhibitor C1inh170 would also be expected to
decrease. Indeed, C1inh levels were decreased in AD vs. ND plasma in both Group 1 (0.59
± 0.20 vs. 1.33 ± 0.43, p = 0.0008; Figure 4.5A,C) and Group 2 (1.0 ± 0.12 vs. 1.2 ± 0.18, p
= 0.012; Figure 4.5D,F), suggesting its consumption due to increased activation of FXIIa,
kallikrein, and/or FXIa.
Activation of the intrinsic pathway of coagulation would be expected to result in
increased thrombosis and fibrin formation. Indeed, plasma fibrin levels (as determined by
monoclonal antibody 59D8 against fibrin175) were elevated in AD patients from Group 2
compared to controls (0.97 ± 0.17 vs. 0.74 ± 0.15, p = 0.009; Figure 4.5G,H). Levels of fibrin
were inversely correlated with FXI levels (r = -0.46, p = 0.04; Figure 4.5I), suggesting that
activation and subsequent clearance of FXI results in thrombin generation and fibrin
formation. In Group 1, there was a non-significant trend toward increased fibrin levels in AD
plasma (not shown), which could be due to differences in blood draw and anticoagulation
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methods between the groups (see Methods 2.21). Another possible explanation stems from
the more advanced disease stage of AD patients in Group 1 compared to Group 2 as
determined by clinical dementia rating score (2.0 ± 1.1 vs. 1.0 ± 0.6, p = 0.028). Since
Group 1 patients are likely to have been exposed to FXI activation for longer due to more
advanced disease, the fibrin formed may have been progressively deposited, thereby
depleting soluble fibrin monomers from plasma.
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Figure 4.5. AD patient plasma has lower levels of FXI and C1inh. (A) Non-reducing
Western blot analysis of FXI, C1inh, and transferrin loading control in plasma of 10 AD
patients and 10 ND controls from Group 1. Lanes loaded with FXI purified protein (FXI) and
FXI-deficient human plasma (FXI-def) show that the band just above the FXI band is nonspecific. (B) FXI levels normalized to transferrin were lower in AD than ND plasma (p=0.008).
(C) C1inh levels were lower in AD than ND plasma (p = 0.0008). (D) Levels of FXI, C1inh,
and transferrin were analyzed in 10 AD and 10 ND plasmas from Group 2. (E) FXI levels
were lower in AD than ND plasma (p = 0.0003). (F) C1inh levels were lower in AD than ND
plasma (p = 0.01). (G) Levels of fibrin monomer were analyzed under reducing conditions in
10 AD and 10 ND plasma samples from Group 2 using antibody 59D8 specific for fibrin beta
chain175. (H) Fibrin levels were increased in AD plasma compared to control (p = 0.009). (I)
Fibrin levels were negatively correlated with FXI levels in samples from Group 2 (r = -0.46; p
= 0.04).
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CHAPTER 5. Aβ42 is proinflammatory via activation of FXII in the AD circulation and
brain parenchyma
5.1. Aβ42 promotes FXII-dependent kallikrein-kinin system activation in plasma
I have shown that Aβ42-mediated activation of FXII can result in FXI activation and
thrombin generation, and that this may occur in AD patient plasma (Chapter 4). Thrombin
generation is not the only possible outcome of Aβ-mediated FXII activation, since FXIIa can
also activate the proinflammatory kallikrein-kinin system (Figure 1.2). Indeed, Aβ has been
shown to trigger FXII-dependent kallikrein generation and HK cleavage in vitro121,122,176, and
increased cleavage of HK occurs in AD patient CSF176. However, activation of the FXIIdriven kallikrein-kinin system has not been shown with oligomeric Aβ42 or in AD patient
plasma.
Since Aβ-mediated contact activation appears to be sensitive to small changes in the
makeup of Aβ preparations (Figure 4.3), I first confirmed the ability of my preparation of
oligomeric Aβ42 to trigger FXII-dependent prekallikrein activation in a purified protein
system (Figure 5.1A). Prekallikrein activation in the presence of Aβ42 was also observed in
normal plasma, as seen through the reduction in 86 kDa prekallikrein zymogen levels
(Figure 5.1B). Incubation of plasma with Aβ42 generated functional kallikrein that cleaved its
substrate HK in a dose-dependent manner, seen as diminished signal intensity of single
chain (uncleaved) HK bands at 120 kDa (Figure 5.1C). Decreases in uncleaved HK levels
were accompanied by the appearance of cleaved HK fragments: the light chain band
migrating at 56 kDa and an additional 45 kDa band representing a degradation product of 56
kDa HK light chain. Aβ42-initiated HK cleavage in plasma was FXII-dependent, since Aβ42
had no effect on HK cleavage in FXII-deficient plasma (Figure 5.1C).
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Figure 5.1. Aβ42 triggers FXII-dependent prekallikrein activation and HK cleavage. (A)
Aβ42 (3 µM) promoted kallikrein generation in the presence of FXII (10 nM) and prekallikrein
(PPK; 10 nM) as measured by chromogenic substrate Pefachrome PK. The specificity of
Pefachrome PK for detecting kallikrein and not FXIIa activity was confirmed by testing 10
nM FXIIa (maximum amount of FXIIa generated in the assay) with no prekallikrein, which
did not result in any substrate cleavage (not shown). (B) Aβ42 (20 µM) and kaolin (100
µg/ml) promoted PPK activation in human plasma. (C) Aβ42 promoted HK cleavage in a
dose-dependent manner in normal but not FXII-deficient human plasma.
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5.2. Increased contact system activation in AD patient plasma (Group 1)
If activation of the FXII-driven kallikrein-kinin system by Aβ occurs in vivo, AD patient
plasma may show evidence of this process. Plasma from AD patients and controls was
obtained from two tissue banks (Methods 2.21). Samples from the University of Kentucky
Sanders-Brown Center on Aging (Group 1) consisted of 18 AD and 11 ND samples matched
with respect to age and gender (Table 1). The extent of dementia in these individual had
been assessed using Clinical Dementia Rating (CDR) scores, where 0 = no dementia and 3
= severe dementia177, as well as Mini Mental State Examination (MMSE) scores, where 30 =
no dementia and 0 = severe dementia178. At the time of blood draw, Group 1 AD cases had
an average CDR score of 1.6 ± 1.3 (range 0-3) and an average MMSE score of 16.5 ± 9.6
(range 0-30), corresponding to moderate dementia. The presence of CDR 0 and MMSE 30
individuals in this group can be attributed to the fact that several (n = 3) were diagnosed with
MCI or AD after blood draw. Upon autopsy, the majority of Group 1 AD cases (77.8%) were
Braak stage 5 or 6, corresponding to severe dementia (Table 1)179.
Plasma FXII activation in Group 1 AD patients and ND controls was analyzed under
reducing conditions, with results reported after normalization to transferrin loading control.
Cleavage of the FXII zymogen (80 kDa) and the appearance of a heavy chain band at 52
kDa were detected in 13 of 18 AD plasmas and 2 of 11 ND plasmas in Group 1 (Figure
5.2A). Levels of the 52 kDa heavy chain fragment, the generation of which typically
corresponds to FXII activation, were higher in AD than in ND cases (0.47 vs. 0.07, p=0.029;
Figure 5.2B).
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Table 5.1. Characteristics of AD and ND cases from Group 1
AD (18)

ND (11)

61

64

Mean age at blood draw (years; SD)

82.4 (9.1)

82.5 (6.3)

Mean CDR at blood draw (score; SD)

1.56 (1.28)

0 (0.2)

Mean MMSE at blood draw (score; SD)

16.5 (9.6)

28.5 (1.5)

0

100

B

27.8

0

C

72.2

0

0-2

16.7

100

3-4

5.6

0

5-6

77.8

0

Hypertension

50

63.6

Atrial Fibrillation

5.6

18.2

Stroke

27.8

0

Diabetes

5.6

18.2

Hypercholesterolemia

38.5#

45.5

Myocardial Infarction

11.1

27.3

Gender (% Male)

CERAD (%)
None

Braak stage (%)

History of (%)

# History of hypercholesterolemia data was available for only 13 AD cases.
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Figure 5.2. Contact system activation in AD patient plasma from Group 1. (A) Western
blot analysis of FXIIa and transferrin loading control in plasma of 18 AD patients and 11 ND
controls from Group 1 (representative samples shown). FXII zymogen is observed at 80 kDa
and the αFXIIa heavy chain at 52 kDa. Lane loaded with FXII-deficient human plasma (FXIIdef) shows that the bands just below and above the FXIIa band are non-specific. (B) FXIIa
levels normalized to transferrin were higher in AD (p = 0.029) than ND plasma. When AD
cases with a history of stroke (n = 5) were excluded from the analysis, FXIIa levels in AD
with stroke-excluded cases (AD SE) remained significantly higher than in ND plasma (p =
0.018). (C) Western blot analysis of HK in representative samples: uncleaved HK is
observed at 120 kDa, HK light chain at 56 kDa, and light chain fragment at 45 kDa. (D)
Uncleaved HK levels normalized to transferrin were significantly lower in AD (p <0.0001)
than ND plasma. When AD cases with a history of stroke (n = 5) were excluded from the
analysis, uncleaved HK levels in AD with stroke excluded cases (AD SE) remained
significantly lower than in ND plasma (p = 0.0002). Red points represent individuals who
developed cognitive decline at least one year after blood draw. (E) Kallikrein-like activity was
higher in AD plasma compared to ND (p = 0.0006). (F) Kallikrein-like activity was correlated
with HK levels (r = 0.81, p <0.0001). (G) HK levels normalized to transferrin were higher in
both individuals with CERAD score B (p = 0.003) and CERAD score C (p <0.0001) than in
individuals with CERAD score 0. Samples were analyzed 3 separate times with similar
results. Results are presented as vertical scatter plots with medians, with statistical
significance determined using the Mann-Whitney test for two-group comparisons and the
Kruskal-Wallis test with Dunn’s Multiple Comparison post-test for comparisons between
multiple groups.
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Activation of FXII may occur in conjunction with co-morbidities present in AD patients
that are absent in controls. However, records of self- or caregiver-reported medical
conditions indicate that AD cases did not have higher levels of hypertension,
hypercholesterolemia, diabetes, myocardial infarction, or atrial fibrillation than controls
(Table 1), arguing against a role for these co-morbidities in the increased FXIIa levels
observed in AD patient plasma. Interestingly, history of stroke was found in 5 of 18 (almost
30%) of AD cases, but was absent in ND cases. Stroke is mediated by thrombosis and/or
vessel rupture, both of which generate surfaces for FXII activation such as
polyphosphates180 and RNA181. However, excluding AD cases with history of stroke did not
substantially change the FXIIa levels in AD and ND groups (0.47 vs. 0.07 respectively, p =
0.018; Figure 5.2B).
The presence of FXIIa in AD patient plasma in Group 1 (Figure 5.2A) was accompanied
by HK cleavage (decreased intensity of bands at 120 kDa; Figure 5.2C). AD plasma as a
group had much lower levels of uncleaved HK than ND plasma (0.01 vs. 1.19, p <0.0001;
Figure 5.2D), even when AD cases with history of stroke were excluded (0.01 vs. 1.19, p =
0.0002; Figure 5.2D). Decreases in uncleaved HK levels were accompanied by the
appearance of cleaved HK fragments at 56 kDa and 45 kDa. Because HK cleavage
products are rapidly degraded182, samples with high levels of HK cleavage did not
necessarily have proportionally higher levels of HK light chain, making quantification of the
HK breakdown products uninformative. Interestingly, some samples (e.g. AD1 and AD2) that
did not have detectable FXIIa showed evidence of HK cleavage, demonstrating that HK
cleavage is a more sensitive indicator of contact activation than FXII activation.
To determine whether the reduction in uncleaved HK levels observed by Western blot is
a result of contact system activation, I measured the activity of plasma kallikrein, the
enzyme responsible for HK cleavage. Kallikrein-like activity, measured by chromogenic
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substrate assay, was higher in AD vs. ND plasma (40.9% vs. 4.5% of fully activated plasma,
p = 0.0006; Figure 5.2E) and correlated with HK cleavage as detected by Western blot (r =
0.81, p <0.0001; Figure 5.2F). Since kallikrein generation is triggered by FXIIa, this result
also indicates that FXII cleavage detected by Western blot represents FXII activation.
When HK levels were plotted as a function of CERAD score (a measure of Aβ plaque
pathology in the brain on autopsy: 0 = normal brain; B = probable AD; C = definite AD147),
plasma from individuals with a CERAD score of 0 had higher levels of uncleaved HK
compared to plasma from individuals with a CERAD score of B (1.19 vs. 0.01, p <0.05) or C
(1.19 vs. 0.01, p <0.001) (Figure 5.2E). The fact that HK cleavage is apparent in the plasma
of individuals with CERAD B and does not increase further in those with CERAD C suggests
that FXIIa-driven inflammation begins early in disease progression and is mostly developed
by the time individuals reach CERAD B status. The idea that HK cleavage is an early event
in AD is also suggested by its presence in plasma from 3 individuals who were cognitively
normal at time of blood draw but went on to develop cognitive impairment (red points in
Figure 5.2D).
5.3. Increased contact system activation in AD patients plasma (Group 2)
Samples from the Washington University Knight Alzheimer’s Disease Research Center
(Group 2) consisted of 10 AD and 10 ND samples matched with respect to age (Table 2).
AD cases in Group 2 had an average CDR score of 1.0 ± 0.6 at the time of blood draw, with
the majority (80%) being CDR 0.5 or 1 (Table 2), corresponding to very mild to mild
dementia177. Group 2 individuals are still living and therefore Braak stages and CERAD
scores are not available.
While FXIIa was not detected in AD or ND plasma from Group 2 (not shown), uncleaved
HK levels were lower in AD than ND (0.59 vs. 0.85; p <0.0001; Figure 5.3A,B). Kallikrein-like
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activity was also increased in AD plasma from Group 2 (1.2% vs. 0.96% of fully activated
plasma, p = 0.03; Figure 5.3C), corroborating the decreased levels of uncleaved HK seen by
Western blot.
Levels of CSF Aβ42, total tau (tau), and phosphorylated tau (p-tau) in Group 2 were
available from the Washington University Alzheimer’s Disease Research Center. Decreased
CSF Aβ42 levels are thought to be the earliest CSF marker of incipient AD, appearing as
early as ~15 years prior to onset of symptoms and remaining low as disease progresses,
while CSF tau and p-tau levels (related to neurofibrillary tangle formation and
neurodegeneration) begin to rise closer to the appearance of cognitive decline (reviewed in
183

). We therefore performed correlation analyses for these CSF biomarkers and uncleaved

HK levels. Levels of uncleaved plasma HK were positively correlated with CSF Aβ42 (r =
0.63; p = 0.003; Figure 5.3C), consistent with increased HK cleavage in the plasma of
individuals with lower CSF Aβ42. Uncleaved plasma HK did not correlate with CSF tau (r = 0.11; p = 0.64; Figure 5.3D) or p-tau (r = -0.25; p = 0.28; Figure 5.3E), suggesting that
increased HK cleavage may be an early event in AD progression that precedes substantial
changes to neuronal injury markers.
Undetectable FXIIa and less dramatic HK cleavage in Group 2 than Group 1 may stem
from the earlier disease stage of Group 2 cases (CDR score Group 2, 1.0 ± 0.6 vs. Group
1,1.6 ± 1.3) and from differences in blood collection. While I show that the degree of contact
system activation may increase with disease progression (Figure 5.3D), the method of blood
collection appears to also play a role, since ND plasma in Group 2 had lower kallikrein
activity than ND plasma in Group 1 (Figures 5.2E, 5.3C).
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Table 5.2. Characteristics of AD and ND cases from Group 2
AD (10)

ND (10)

30

50

Mean age at blood draw (years; SD)

73.6 (5.8)

70.5 (3.9)

Mean CDR at blood draw (score; SD)

1.0 (0.6)

0 (0)

0

0

100

0.5

40

0

1

40

0

2

20

0

Gender (% Male)

CDR (%)
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Figure 5.3. Contact system activation in AD patient plasma from Group 2. (A) Western
blot analysis of HK and transferrin loading control in plasma of 10 AD patients and 10 ND
controls from Group 2. (B) Uncleaved HK levels normalized to transferrin were significantly
lower in AD (p <0.0001) compared to ND plasma. (C) Kallikrein-like activity was higher in AD
plasma compared to ND (p = 0.03). (D) Levels of CSF Aβ42, which decrease with AD, were
positively correlated with uncleaved HK levels (r = 0.63, p = 0.003). (E) Levels of CSF tau,
which increase with AD, were not correlated with uncleaved HK levels (r = -0.11, p = 0.64).
(F) Levels of CSF p-tau, which increase with AD, were not correlated with uncleaved HK
levels (r = -0.25, p = 0.28). Samples were analyzed 3 separate times with similar results.
Results are presented as vertical scatter plots with medians, with statistical significance
determined using the Mann-Whitney test.
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5.4. Blood draw method and detection of contact system activation
In Group 1, blood was drawn into plastic heparinized Vacutainer tubes via vacuum, while
Group 2 blood was drawn into EDTA-coated syringes via aspiration. Heparin can promote
contact system activation in a purified protein system184 and in plasma diluted to 30%185, but
not in plasma diluted to 90%186, arguing against heparin-mediated activation of undiluted
blood during collection. On the other hand, EDTA is a Zn++ chelator and may therefore
prevent ongoing contact activation after blood collection, resulting in detection of less FXIIa
and uncleaved HK in Group 2. To test these possibilities, I evaluated the activation potential
of blood from WT mice collected into heparin or EDTA (in collaboration with Zu-Lin Chen in
the Strickland laboratory). Both EDTA- and heparin-anticoagulated plasma treated with the
FXII activator dextran sulfate had comparably decreased levels of uncleaved HK (Figure
5.4), indicating that heparin-mediated promotion or EDTA-mediated inhibition of ex-vivo FXII
activation cannot explain the differences between Groups 1 and 2. However, the possibility
remains that long-term storage of frozen plasma with EDTA vs. heparin could lead to
differences in ex-vivo contact activation.
Another possible explanation is that collection of blood into Vacutainer tubes is more
likely to trigger FXII activation compared to slower blood draw into syringes (personal
communication, Thomas Renné; Karolinska Institute). Indeed, plasma collected into
Vacutainer tubes (with vacuum) has increased FXII-driven thrombin generation187 and
earlier clot formation188 compared to blood drawn into S-Monovette tubes, which employ a
syringe-like mechanism. Thus, blood draw methods used for Group 1 may have resulted in
ex-vivo amplification of smaller differences in contact factor activation present in vivo, which
did not occur in Group 2.
It is important to note that there are limitations to my analysis of AD patient and ND
control plasma inherent to the discontinuous chain of custody of the samples and potential
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variability in sample storage, which could both play a role in ex-vivo activation of plasma
proteins. While storage times were similar between AD and ND samples in Group 2, Group
1 AD samples were (on average) stored for a longer time than ND samples. However,
excluding some samples (AD = 3; ND = 3), and thereby equalizing average storage times
between AD and control samples, did not alter the results (not shown).
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Figure 5.4. Blood draw into EDTA or heparin does not affect ex-vivo contact activation.
Blood from C57Bl/6 mice (n = 3) was drawn with EDTA or heparin anticoagulants as
described in Methods 2.24. Plasma was activated with dextran sulfate (DXS), 0.1 µg/ml final
concentration, or vehicle for 20 min at 37°C, and reactions stopped with reducing sample
buffer. (A) Western blot analysis of plasma with an antibody against mouse HK (mHK).
Mouse plasma contains mHK and mHK-∆D5 (mHK lacking domain 5)189, observed at ~110
kDa and 82 kDa, respectively. (B) Uncleaved (sum of both mHK and mHK-∆D5 bands) is
decreased in samples activated with DXS compared to vehicle in both EDTA and heparin
conditions (p <0.05).
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5.5. Contact system activation in AD mice and in WT mice injected with Aβ42
AD patients are a heterogeneous population with various disease etiologies and
comorbidities. To analyze HK cleavage in a more homogeneous model, we examined
plasma from the Tg6799 mouse model of AD, in which AD pathology is driven by the
overexpression of human Aβ142 (hereafter referred to as AD mice; mouse experiments were
done in collaboration with Zu-Lin Chen). Since detection of FXIIa by Western blot in mouse
plasma is technically challenging given the poor ability of antibodies to recognize murine
FXIIa fragments (not shown), we focused on HK cleavage as a marker of contact system
activation. Compared to non-transgenic wild type littermate controls (WT), AD mice had
decreased levels of uncleaved HK (2.0 vs. 1.6, p = 0.0012; Figure 5.5A,B). These data
corroborate HK cleavage in human AD patient plasma and also support the idea that the
increased HK cleavage in AD patient plasma is related to Aβ-driven AD pathology and not to
comorbidities present in AD patients.
We next investigated whether the increased HK cleavage found in AD patient and
mouse model plasma could be mediated by Aβ42, an aggregation-prone, negativelycharged peptide. To control for non-specific effects, scrambled Aβ42 as well as amylin,
another aggregating peptide, were used. Peptide preparations were shown by TEM to be
composed of similar sized structures (Figure 5.5C). Incubation of Aβ42 but not scrambled
Aβ42, amylin, or vehicle with WT mouse plasma resulted in HK cleavage (not shown),
confirming results obtained with human plasma121,123. Wild type (WT; C57BL/6) mice were
then intravenously injected with the same peptides or vehicle. Plasma from mice injected
with Aβ42 but not scrambled Aβ42 or amylin had decreased levels of uncleaved HK (2.8 ±
0.8 vs. 4.5 ± 1.0, p <0.01; Figure 5.5D,E) and increased kallikrein-like activity (73.0 ± 38.2%
vs. 4.9 ± 1.9% of fully activated plasma, p <0.001; Figure 5.5F) compared to plasma from
mice injected with vehicle. The presence of Aβ42 in the blood of injected mice was
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confirmed by ELISA (17.1 ± 9.0 ng/ml in Aβ42-injected mice compared to undetectable
levels in vehicle-injected mice; lower limit of detection = 0.0156 ng/ml; Figure 5.5G). Aβ42mediated activation of the contact system in vivo (as determined by kallikrein activity in
plasma) was both dose (r = 0.92, p <0.0001; Fig. 5.5H) and FXII-dependent, since injection
of Aβ42 into FXII-/- mice did not result in increased kallikrein activity (Fig. 5.5I). Our
combined results indicate that circulating Aβ42 functions as a FXII contact activator capable
of triggering kallikrein activity and HK cleavage in vivo, and support the hypothesis that
increased HK cleavage in AD patient and mouse model plasma is due to Aβ42-mediated
FXII activation.
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Figure 5.5. Contact system activation in plasma from an AD mice and from wild type
mice injected with Aβ42. (A) Plasma from AD mice (n = 7) and littermate controls (WT; n =
7) was analyzed by Western blot with an antibody against mHK; representative lanes shown.
(B) Levels of uncleaved mHK (sum of both mHK and mHK-∆D5 bands) normalized to
transferrin were lower in AD than WT mice (p = 0.0012). (C) Representative TEM images of
Aβ42, scrambled (scr) Aβ42, and amylin used for injections. Scale bar = 100 nm. (D)
Representative lanes from blot probed with an antibody against mHK light chain showing
C57BL/6 mice injected with vehicle, Aβ42, Aβ42 scr, or amylin. (E) The level of uncleaved
HK normalized to transferrin was significantly lower (p <0.001) in mice injected with Aβ42
than in vehicle-, Aβ42 scr-, or amylin-injected mice. (F) Kallikrein activity as measured by
chromogenic substrate was increased in plasma from mice injected with Aβ42 but not Aβ42
scr or amylin compared plasma from mice injected with vehicle (p <0.001). (G) Plasma Aβ42
levels in C57BL/6 mice injected with Aβ42 were significantly higher than in mice injected
with vehicle (p = 0.001). In mice injected with vehicle, levels of Aβ42 were below the
detection limit of the ELISA (0.0156 ng/ml). (H) The dose of Aβ42 (0, 3, 6, or 9 mg/kg Aβ42)
injected into WT mice (n = 4 per dose) correlated with kallikrein activity levels in plasma (r =
0.92, p <0.0001). (I) Kallikrein activity was increased in WT (n = 4 per group; p <0.01) but
not in FXII-/- mice injected with 6 mg/kg Aβ42 (n = 6 per group). Results are presented as
vertical scatter plots with medians for panels B, G, and I, and with means for panels E and F,
with statistical significance determined using the Mann-Whitney test for panels B and G,
ANOVA with Dunnett’s post-test for E and F, and Kruskal-Wallis with Dunn’s post-test for I.
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5.6. Contact system activation in AD brain parenchyma
Activation of FXII by Aβ42 may occur not only in the circulation, but also in the brain
parenchyma, where many components of the contact activation system are found190-194.
Evidence of activation of these systems in AD is limited to increased plasma kallikrein
activity in brain parenchyma193 and elevated levels of cleaved HK in CSF176. However, the
presence and cleavage of HK in the AD brain parenchyma has not been investigated.
Two mouse models of AD (TgCRND8 and Tg6799, see Methods 2.17 for details) were
used to analyze contact system activation in the brain parenchyma as a function of age and
hence disease progression. Marta Cortes-Canteli from the Strickland laboratory provided
brain tissue and homogenates for all experiments described below. FXII was detected in
both TgCRND8 and Tg6799 but not WT littermate control brains by immunofluorescence
(Figure 5.6A; representative images from 35 week old Tg6799 mice and littermate controls
probed with two anti-FXII antibodies are shown). FXII immunoreactivity surrounded Aβ
immunoreactive regions in a halo-like pattern (Figure 5.6A), suggesting that FXII interacts
with Aβ and corroborating results in AD patient brains190. The co-localization of FXII and Aβ
was detected at 16 weeks of age in the TgCRND8 model (Figure 5.6B), around the time
cognitive dysfunction first begins to appear, suggesting that FXII presence in the brain is not
a consequence of late-stage disease. The presence of FXII in the brain at earlier time points
has not yet been analyzed. Whether the FXII detected is produced locally or is a result of
plasma protein extravasation across the BBB is unclear, although the presence of diffuse
FXII immunoreactivity in WT brains (WT panels in Figure 5.6A,B) together with previous
identification of FXII mRNA in the brain190,192 argues for local production.
Co-localization between Aβ and FXII suggests that contact activation occurs in AD
mouse model brains, which could result in bradykinin release from HK. While no HK was
detected by Western blot in TgCRND8 (AD) or littermate control (WT) brains at 4- and 15
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weeks (Figure 5.6C), increased HK levels were found in 58- and 82 week old AD vs. WT
brains (Figure 5.6D, p <0.01 at 58 weeks, p <0.001 at 82 weeks). It is possible that
differences in brain HK levels exist at or before 15 weeks, but that the antibodies used are
not sufficiently sensitive to detect them. The presence of HK in AD mouse brain was
confirmed by HK immunofluorescence, where it also co-localized with regions of Aβ
accumulation (not shown). When the same samples were analyzed under reducing
conditions (which separate the heavy and light chains of cleaved HK, clearly demonstrating
HK cleavage), no signal was detected in AD or WT mice at any age. This suggests that the
HK detected under non-reducing conditions represents cleaved HK, light chain fragments of
which are rapidly degraded under reducing conditions (see for example the low level of HK
light chain fragment in lane AD10, Figure 5.3C; when that blot is run under non-reducing
conditions, lane AD10 shows a very strong HK signal, not shown).
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Figure 5.6. FXII and HK in AD mouse model brain. (A) Representative confocal
microscopy images of cortex from 35 week old Tg6799 (AD) and littermate control (WT)
mice stained with antibodies against Aβ (green) and FXII (red – two different antibodies
shown). DAPI staining is in blue. (B) Representative confocal microscopy images of cortex
from 16 week old TgCRND8 (AD) and littermate control (WT) mice stained with antibodies
against Aβ (green) and FXII (red). (C) Non-reducing Western blot analysis of soluble fraction
from whole brain homogenates of TgCRND8 (AD) or littermate control (WT) mice at different
ages (n = 3 for each group). Blots were probed with antibodies against mouse HK and
tubulin as loading control. Under non-reducing conditions, mHK and mHK-∆D5 migrate
together. (D) Levels of HK normalized to tubulin were increased in AD vs. WT mice at 58- (p
<0.01) and 82 weeks (p <0.001) by 2-way ANOVA with Bonferroni post-test.
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5.7. HK accumulation and cleavage in AD patient brain parenchyma
The presence and cleavage of HK in human AD brain was analyzed in brain tissue from
the Harvard Brain Tissue Resource Center obtained and processed by Marta Cortes-Canteli.
AD patients were defined as being Braak stage 3-6, while ND controls were Braak stage 02195 and matched with respect to age. Homogenates were prepared from the temporal pole
region, which is strongly affected by Aβ plaques, tau pathology, and neuronal loss in
AD196,197.
Reducing western blot analysis of the soluble protein fraction from temporal pole tissue
showed both uncleaved HK at 120 kDa and cleaved portions of the HK light chain (HKa) in
AD and ND brains (Figure 5.7A, top panel). Levels of total HK (cleaved and uncleaved)
normalized to actin were dramatically increased in AD brains (p = 0.012; Figure 5.7B) and
correlated with Braak stage (r = 0.77, p <0.0001; Figure 5.7C). Brain HK accumulation was
accompanied by HK cleavage, as seen through the appearance of cleaved HK light chain
bands (Figure 5.7A), levels of which were significantly increased in Braak 6 AD brains
compared to ND (p <0.05; Figure 5.7D) and correlated with Braak stage (r = 0.57, p = 0.008;
Figure 5.7E). Cleaved HK levels in all AD vs. ND brains almost achieved significance (p =
0.053), and would likely do so with more samples. Interestingly, the ND sample in lane 4
(arrow) that had the highest level of cleaved HK fragments was at Braak stage 2, which is
one stage prior to what is defined as clinical AD195. Together, these results suggest that HK
accumulation and cleavage in the temporal pole are linked to disease onset and progression,
and may be an early process in AD development.
HK is an abundant plasma protein, and its increased presence in the AD brain could be
explained by extravasation across a pathologically permeable BBB, known to occur in AD38.
Brain levels of the plasma protein albumin also correlated with Braak stage (Figure 5.6A,
third panel and 5.7F; r = 0.87, p <0.0001), supporting increased plasma protein
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extravasation in AD. Although not widely reported, microglia have been shown to express
albumin in vitro and in human AD brain tissue, and this expression is increased following
microglial activation by Aβ42198. Thus, AD brains (which are characterized by Aβ42
accumulation) would be expected to have higher levels of albumin independent of BBB
permeability. Indeed, levels of other plasma proteins such as hemoglobin and fibrinogen are
not increased in AD brains (Figure 5.7A, fourth and fifth panels), indicating that non-specific
extravasation of plasma proteins in AD cannot account for the increased brain HK levels
observed.
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Figure 5.7. Increased HK accumulation and cleavage in AD patient brain. (A) Reducing
Western blot analysis of the soluble fraction from the temporal pole in AD (Braak stage 3-6)
and ND (Braak stage 0-2) brains. Purified uncleaved HK and cleaved HK (HKa) were loaded
as controls. Blots were probed with antibodies against HK, actin, albumin, hemoglobin, and
fibrinogen. A possible concern is that uncleaved HK may be absent in the first two ND
samples because it has been fully cleaved and HKa bands further degraded. Non-reducing
Western blot confirmed that the first two ND samples had very low levels of HK, and that
cleaved HK was not being missed (not shown). (B) Levels of total HK (sum of uncleaved
and both cleaved bands) normalized to actin were higher in AD vs. ND brains (p = 0.0123).
(C) Total HK normalized to actin correlated with Braak stage (r = 0.77, p <0.0001). (D)
Levels of cleaved HK normalized to actin were increased in Braak 6 AD patients compared
to ND controls (p <0.05) and were trending higher in other AD groups. (E) Levels of cleaved
HK normalized to actin correlated with Braak stage (r = 0.57, p = 0.008). (F) Levels of
albumin normalized to actin correlated with Braak stage (r =0.87, p <0.0001).
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CHAPTER 6. DISCUSSION
6.1. Overview
In this thesis, I established the ability of Aβ to initiate prothrombotic and inflammatory
processes via activation of the FXII-driven contact system, and provided evidence for these
processes in AD patients and mouse models. I also defined the regions involved in Aβ42fibrinogen binding and elucidated the mechanism by which this interaction results in delayed
fibrinolysis. Together, these results provide a basis for a novel hypothesis for the etiology of
the vascular dysfunction that may play a key role in AD onset and progression. I will first
discuss the results independently, then present the hypothesis derived from my combined
findings.
6.2. The Aβ-fibrin(ogen) interaction and Aβ’s role in clot susceptibility to fibrinolysis
The Strickland laboratory has identified Aβ42 as a novel factor capable of modulating
fibrin clot structure and stability. Results in Chapter 3 defined mechanisms by which fibrin
clots formed in the presence of Aβ42 become more resistant to fibrinolysis and suggested
mechanisms by which clot structure is altered. Structural and biochemical evidence supports
the following hypothetical model (Figure 6.1) for the Aβ-fibrinogen interaction: The Cterminal half of Aβ42 (residues 17-42) binds to fragment D of fibrinogen on the globular
domain of its beta chain, near the b-hole (β366-414; Figures 3.1-3.3). Since the b-hole is
involved in the lateral aggregation of fibrin protofibrils199, Aβ binding to this region may
interfere with thickening of the fibrin network during clot formation, resulting in a thinner
network (Figure 3.9). From the b-hole, Aβ stretches along the coiled-coil portion of fragment
D, with the N-terminal portion of Aβ contacting the α-chain within this coiled-coil region.
Since Aβ binds to fibrin fibers throughout the network (Figure 3.9) and not just to clumps as
previously thought59, it could hinder the binding of plasminogen to fibrin at residues α148160160, thereby reducing network-wide plasmin generation and function.
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Aβ may be introduced into fibrin clots in two ways, by intercalation into fibrin fibers during
clot formation and by penetration into pre-formed clots. This is an important point, indicating
that Aβ released from activated platelets126,200 can alter fibrin’s susceptibility to lysis after the
clot has formed. The oligomeric state of Aβ42 required for delayed fibrinolysis has also been
clarified: While Aβ oligomerization is necessary for delayed fibrinolysis (Figure 3.12), the
formation of Aβ42 fibrils, which appear to induce clumping of the fibrin network (Figure
3.12E,I), is not. Although we previously hypothesized that clumps mediate delayed
fibrinolysis59, my current in vitro data indicate that two other mechanisms are responsible for
the increased stability of Aβ42-influenced clots: thinning/tightening of the fibrin network and
Aβ42-mediated hindrance of plasmin(ogen)’s access to fibrin.
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Figure 6.1. Model of the interaction between Aβ42 and fibrinogen fragment D. A ribbon
diagram of fibrinogen fragment D (PDB 1FZA; light blue)132 with the 49 amino acid binding
region (β366-414) for Aβ labeled in red and the β-chain loop that undergoes a shift in the
presence of Aβ (β384-393) labeled in green. Alpha-chain residues implicated in
plasminogen binding (α 148-160), which is inhibited in the presence of Aβ, are in gold. My
combined results suggest that Aβ (hypothetical position represented in pink) binds to β366414 (red) with its C-terminal end, which results in a shift of the loop defined by β384-393
(green). The N-terminal end of Aβ extends toward the coiled-coil region of fragment D,
thereby blocking α148-160 (gold) necessary for plasminogen binding. The b-hole, centered
around residues β397, β398201, and β432202 (teal), is implicated in lateral aggregation of
fibrin protofibrils. Blocking of the b-hole by Aβ may contribute to the formation of thinner
fibrin fibers.
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The interaction between Aβ and fibrin(ogen) in the cerebral circulation and brain
parenchyma may therefore support increased thrombosis and fibrin accumulation, which are
obstructive and proinflammatory, thereby contributing to AD pathology59,203. Indeed, vessel
narrowing and occlusion caused by persistent fibrin(ogen) deposits co-localizing with Aβ
were shown to contribute to impaired perfusion and reduced density of functional cortical
microvessels in a mouse model of AD204. Furthermore, increased fibrin accumulation in the
AD brain negatively affects synaptic health, and genetically decreasing fibrinogen in an AD
mouse model ameliorates synaptic dysfunction and neuronal death205. The relevance of the
Aβ-fibrinogen interaction to these processes is supported by studies demonstrating that
inhibiting this interaction results in restored fibrinolysis in vitro and amelioration of prothrombotic phenotype, microgliosis, and cognitive performance in a mouse model of AD206.
6.3. Aβ is a prothrombotic factor via activation of FXII
My results identify Aβ42 as a prothrombotic factor based not only on its ability to delay
fibrinolysis (Chapter 3), but also on its ability to trigger thrombin generation via the intrinsic
coagulation pathway (Chapter 4). Aβ42 oligomers triggered FXII-dependent activation of FXI,
the first step of the intrinsic pathway, via a template mechanism (Figure 4.3), i.e. by binding
and co-localizing contact activation factors. Aβ42-induced thrombin generation required the
presence of phospholipids (Figure 4.1D), suggesting that while Aβ42 can serve as a surface
for FXII-dependent FXI activation, phospholipid surfaces (necessary for efficient assembly of
downstream coagulation cascade complexes) are required in order for thrombin generation
to proceed.
Aβ42-mediated, FXII-dependent FXI activation was previously not found122, likely due to
the fact that amorphous aggregates of Aβ42 with the Dutch mutation (E22Q) were used.
While Maas et al. found absolutely no FXI activation with Aβ42 Dutch amorphous
aggregates, my results with Aβ42 Dutch oligomers showed low levels of FXII-dependent FXI
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activation (Figure 4.3I). Thus, the assembly state of Aβ42 Dutch (amorphous aggregates vs.
oligomers) plays an important role in determining its ability to induce FXI activation, a
relationship also observed for Aβ42 (Figure 4.3G). Aβ42 oligomers were still much more
potent in FXII-dependent FXI activation than Aβ42 Dutch oligomers, which may stem from
differences in peptide charge (-2.7 for Aβ42 vs. -1.7 for Aβ42 Dutch at pH 7). A specific
negative charge and/or the presence of glutamic acid at position 22 of Aβ42 therefore
appears crucial for its interaction with and/or activation of FXII and FXI. Although the role of
negative charge in Aβ’s ability to bind and activate FXII remains to be established,
preliminary results suggest that the binding of Aβ42 to FXII is not negative chargedependent, but its ability to activate FXII is (not shown).
Other physiological surfaces such as collagen207, polyphosphates180, and RNA181 have
been shown to stimulate FXII-dependent FXI activation and thrombin generation. These
surfaces are brought into contact with circulating FXII during vascular injury, cell death, and
platelet activation. Aβ, however, is constantly present in the circulation, where it exists in a
dynamic equilibrium with brain Aβ208. In AD, circulating Aβ may contribute to continuous lowlevel FXII-dependent FXI activation, a hypothesis supported by decreased plasma levels of
FXI zymogen and its inhibitor C1inh in AD patients compared to controls (Figure 4.5).
Decreased levels of FXI and C1inh could reflect the clearance of the FXIa-C1inh complex
following FXI activation209. Chronic FXI activation in AD could mediate the production of low
“idling” levels of thrombin, which may contribute to the maintenance of a prothrombotic state
in AD.
The ability of circulating Aβ to trigger thrombin generation via FXII adds to its previously
identified prothrombotic roles, including Aβ-mediated formation of fibrinolysis-resistant fibrin
clots (See section 6.2) and Aβ-mediated platelet activation210-212. A combination of these
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effects may participate in the establishment of the prothrombotic state observed in AD
(Section 1.4).
6.4. Aβ is a proinflammatory factor via activation of FXII
FXII-dependent prekallikrein activation and subsequent HK cleavage by some Aβ40 and
Aβ42 preparations has been shown in vitro121-123. In Chapter 5, I established that oligomeric
Aβ42 is also capable of FXII-dependent prekallikrein activation and HK cleavage (Figure
5.1), and showed for the first time increased FXII activation, kallikrein activity, and HK
cleavage in AD patient circulation. HK cleavage correlated with early CSF biomarkers of AD
(Figures 5.2, 5.3), suggesting that FXII-mediated kallikrein-kinin system activation is an early
process in disease development that plateaus at more advanced stages. In collaboration
with Dr. Zu-Lin Chen, I demonstrated that Aβ42 injected intravenously triggers kallikreinkinin system activation in mice, providing a mechanism for increased plasma HK cleavage in
AD patients and mouse models (Figure 5.5). Previously, HK cleavage in AD patient plasma
was not detected176, possibly due to the inclusion of polybrene in blood collection tubes in
that study. Thus, chronic activation of the FXII-driven kallikrein-kinin system by Aβ42 in the
AD circulation may induce constant low levels of bradykinin-mediated inflammatory
processes, including increased BBB permeability, increased extravasation of plasma
proteins in the brain parenchyma, and cytokine up-regulation106,213, all observed in AD24,38.
My results suggest that activation of the FXII-driven kallikrein-kinin system by Aβ may
contribute to AD pathology not only in the circulation, but also in the brain parenchyma. The
co-localization of FXII with Aβ deposits in the cortex of AD mice (Figure 5.6A) and AD
patients190 implicates Aβ-mediated FXII activation in the brain, supported by higher kallikrein
activity in AD brain193 and by increased HK cleavage AD CSF214. My results indicate that HK
accumulation and cleavage in the brains of AD mice (Figure 5.6C,D) and patients (Figure
5.7) correlate with disease progression, suggesting that activation of the kallikrein-kinin
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system may play a pathological role. It is unclear whether HK accumulation results from
non-specific plasma protein extravasation through a more permeable BBB in AD38 or arises
through other mechanisms, since not all plasma proteins tested were observed to
accumulate in the brain with disease progression (Figure 5.6).
6.5. Aβ levels in AD patients
My hypothesis that Aβ42 contributes to thrombosis and inflammation by interacting with
FXII requires the co-localization of Aβ42 with FXII at sufficient levels in the brain
parenchyma and/or circulation. FXII is abundant in the circulation and has been found in the
brain parenchyma190, thus being available in both compartments relevant to my data. Levels
of Aβ42 in AD brain tissue are higher than in the ND brain215 and may begin to accumulate
up to 20 years before disease onset216,217, allowing the Aβ-FXII interaction to be an early
disease process. In plasma, reported concentrations of Aβ are in the picomolar range215, but
these levels are likely to be underestimated due to binding of Aβ to plasma proteins and
erythrocytes218. Indeed, techniques that measure total bound and unbound plasma Aβ have
found concentrations in the nanomolar range218, similar to doses used to demonstrate a
prothrombotic effect (Figure 4.1). Furthermore, much lower concentrations of Aβ than those
required to demonstrate an acute effect in vitro may have significant effects on thrombosis
and inflammation over the many years of AD development.
If increased contact system activation observed in AD patient plasma is a result of Aβ42mediated FXII activation, levels of plasma Aβ42 would be expected to be elevated prior to
AD onset and during AD development. While studies of high-risk populations for AD (Down
syndrome patients, familial AD patients, and family members of AD patients) demonstrate
increased plasma Aβ42 concentrations compared to controls219,220, the relationship between
circulating Aβ42 levels and sporadic AD progression is less clear: cross-sectional studies of
plasma Aβ42 have produced inconsistent results, while longitudinal studies have generally
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found higher Aβ42 levels prior to and just at the onset of AD symptoms with a subsequent
decrease219-221. This suggests that increases in plasma Aβ42 are early event in AD
development, and supports Aβ42-mediated FXII activation as an early pathological process
preceding the onset of symptoms.
While elevated levels of Aβ42 prior to AD onset would directly facilitate contact system
activation, its levels in more advanced disease stages do not necessarily need to be
elevated, since changes to the vasculature that precede and accompany AD42 may create
an environment that allows Aβ42 levels that cannot activate FXII in normal individuals to
produce a pathological effect.
6.6. A new role for circulating Aβ in the development of vascular dysfunction and AD
The model illustrated in Figure 6.2 presents new mechanisms by which circulating Aβ
may lead to vascular dysfunction and contribute to AD onset through FXII-dependent
prothrombotic and inflammatory processes. Inflammation and coagulation are highly
regulated systems that are typically activated in response to injury. In the proposed model,
FXII activation by Aβ induces mild but chronic inflammation and thrombosis in the absence
of injury, which, in the presence of subtle age- or disease-related inflammatory processes,
can rise above threshold levels and contribute to AD onset and progression.
Age- and genetics-associated decreases in the ability of clearance mechanisms to
balance brain Aβ production9,222,223 may result in compensatory increased transport of Aβ
across the BBB into the circulation. Elevated plasma Aβ levels, a risk factor for AD224-227,
initiate pathological processes by triggering FXIl activation, leading to the generation of
thrombin and bradykinin (Figure 6.2, Stage 1A). Alternatively, AD risk factors such as
advanced age and vascular disease states may set the stage for AD development by
producing changes in vessel wall biology34,42,47, inflammatory potential228, and platelet
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activation state229. The resulting reduction in the thromboresistance of the vascular
endothelium, increased activation of inflammatory pathways, and facilitated coagulation
factor assembly on the surface of pre-activated platelets could allow normal levels of
circulating Aβ to have prothrombotic effects (Figure 6.2, Stage 1B).
At this point, thrombin and bradykinin induce small, localized changes to endothelial
function and BBB permeability, further contributing to the prothrombotic and inflammatory
environment99,100,104,106 (Figure 6.2, stage 2). Due to significant cross-talk between
prothrombotic and inflammatory processes104,230-232, activation of inflammation and
coagulation by Aβ is mutually reinforcing. Non-occlusive fibrin clot formation resulting from
limited activation of the intrinsic coagulation and platelets may occur at these early levels of
endothelial cell modification233 (Figure 6.2, Stage 3). Fibrin clots forming in the presence of
Aβ would have increased resistance to fibrinolysis, enhancing their procoagulant and
inflammatory potential. Initial non-occlusive thrombus formation aggravates endothelial
dysfunction234, BBB permeability235 and inflammatory state236, and the resulting leakage of
plasma components into the vessel wall leads to stiffening of the vessel and narrowing of
the lumen, which decrease CBF and induce hypoperfusion28,115,237. Vessel stiffening
combined with CBF disturbances also decrease the drainage of brain interstitial fluid along
perivascular spaces, promoting Aβ accumulation in the brain238,239.
Severe endothelial dysfunction combined with accumulating procoagulant factors can
result in occlusive clot formation (Figure 6.2, Stage 4), which exacerbates hypoxic
conditions and plasma protein extravasation into the brain parenchyma240. The combined
effects of hypoxia and plasma protein leakage can induce astrocyte and microglial
activation241-243. Glial activation87 and CBF disruption244,245 are early events in AD
development that can directly contribute to brain Aβ deposition, neurofibrillary tangle
formation, and neuronal dysfunction24,29,46,49,50, the pathological hallmarks of AD.
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Figure 6.2. Model schematic. Stage1A. Increased transport of Aβ across the BBB due to
age-related dysregulation of other clearance mechanisms results in elevated local levels of
circulating Aβ, which lead to thrombin (Thr) and bradykinin (BK) generation through FXIIdriven contact system activation. Stage 1B. Alternatively, changes to vascular biology,
inflammatory potential, and platelet activation state caused by aging and/or vascular risk
factors create an environment where normal levels of Aβ trigger FXII activation. Stage 2.
Thrombin and bradykinin induce increased BBB dysfunction, BBB permeability, and cytokine
release via interactions with their receptors on endothelial cells. Stage 3. Once a threshold
level of platelet- and intrinsic coagulation pathway activation is achieved, non-occlusive clots
begin to form. These clots are more resistant to degradation due to Aβ-mediated
stabilization of the fibrin network (blue mesh), resulting in prolonged proinflammatory and
prothrombotic damage to the BBB. Plasma protein extravasation (blue shapes) induces
vessel wall changes resulting in dysregulated clearance of Aβ through perivascular drainage
and in decreased CBF. Stage 4. Occlusive clot formation exacerbates hypoxic conditions,
BBB dysfunction, and extravasation of plasma components. Stage 3 and 4 changes can
elicit vessel narrowing, decreased CBF, parenchymal Aβ deposition, tau phosphorylation,
glial activation, and finally neuronal dysfunction.

106

6.7. Testing the model with existing evidence
The model proposed above implies that modulating the functional levels of Aβ and/or
members of the coagulation and kallikrein-kinin pathways in AD should ameliorate or
exacerbate pathological processes initiated by contact system activation (i.e. BBB
dysfunction, thrombosis, inflammation, and cognitive decline). Several lines of evidence
indicate that this is indeed the case. In an AD mouse model, sequestration of Aβ by active
immunization results in restoration of BBB integrity in aged mice and prevents BBB
dysfunction when administered to young mice246. By contrast, intravenously injected Aβ
increases BBB permeability in animal models247-249. Chronic cerebroventricular infusion of
Aβ into rats induces bradykinin generation and subsequent AD-like pathology250, and
pharmacological inhibition or genetic depletion of bradykinin receptors in AD mice results in
reduced inflammation251, normalized CBF responses, and improved cognitive function252,253.
Finally, plasma levels of C1 esterase inhibitor (which inhibits FXIIa, kallikrein, and FXIa) are
decreased in prodromal AD254, suggesting that defects in the ability to control contact
system activation may participate in disease onset and development, or that ongoing
contact activation is depleting its levels.
The end product of the intrinsic pathway of coagulation is thrombin, which induces
inflammation and mediates the conversion of fibrinogen to fibrin. Long-term inhibition of
thrombin activity in AD mouse models decreases cerebrovascular inflammation255, reduces
Aβ accumulation76 and improves cognitive function77. Inhibiting the coagulation cascade at
multiple points with warfarin improves cognitive function in AD patients73-75. Inducing
persistent fibrin accumulation in an AD mouse model by inhibiting fibrinolysis exacerbates
BBB permeability and neuroinflammation, while decreasing fibrinogen levels results in
improved BBB function203 and cognitive performance59. Importantly, interfering with the Aβfibrinogen interaction reduces thrombotic tendency and improves cognitive performance in
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an AD mouse model206. Together, these results support a role for Aβ-induced activation of
the contact system and for Aβ-mediated fibrin stability in eliciting vascular pathology and
cognitive dysfunction in AD.
Additional support for the model comes from striking similarities between the disease
course implied by the described mechanisms and the pathological cascade of cerebral small
vessel disease (SVD). SVD is associated with AD256,257, increases AD risk43, leads to AD
pathology in animal models258 and humans259, and is found in the majority of AD
patients30,237. SVD presents with degenerative changes in arteriolar vessel walls in the deep
white and deep gray matter. These changes are accompanied by plasma component
leakage into the vessel wall and perivascular tissue and can result in stroke and cognitive
decline115. The trigger for the initiating event in SVD development, which is thought to be
endothelial dysfunction102,115, remains elusive.
Since the development of SVD (through endothelial dysfunction, BBB permeability, and
plasma protein extravasation) mirrors the AD mechanism proposed in Figure 6.2, it is
possible that SVD is a precursor to AD, and that the mechanisms for these disorders share
a common trigger. Recent work has shown that in SVD, stalled erythrocytes accumulate in
areas of future BBB breakdown and may thus initiate disease by an unknown mechanism233.
Given that up to 50% of Aβ is bound to erythrocytes220, it is tempting to speculate that the
elusive trigger for SVD onset is Aβ-mediated contact system activation, which may induce
thrombosis and BBB dysfunction (Figure 6.2). This connection is supported by the
observation of small non occlusive clots near stases233 and by correlations between plasma
Aβ levels and pathological markers of SVD such as infarcts and white matter lesions260-262.
Aβ-mediated contact system activation could thus contribute to localized edema,
extravasation of plasma components, consequent stenosis of vessels, and hypoperfusion
leading to SVD development and subsequent AD onset.
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6.8. AD diagnosis and therapy
A definitive AD diagnosis has traditionally been established upon post-mortem
histological analysis of the brain, since a clinical diagnosis of cognitive decline is not
necessarily specific to AD. Diagnostic challenges have hampered therapeutic efforts:
Because clinically-measurable cognitive decline in AD is thought to manifest after significant
pathological changes have occured263, treatment of symptomatic individuals may have
limited efficacy (due to the advanced nature of disease processes).
As research has focused on earlier stages of disease, it has become clear that
pathological markers of AD, such as parenchymal Aβ accumulation, develop gradually and
can precede cognitive and behavioral symptoms by 15-20 years2,183,216,217. Recent advances
have made it possible to detect changes in Aβ homeostasis in living individuals using
amyloid imaging techniques like Positron Emission Tomography with Pittsburgh compound
and by measuring Aβ levels in the CSF. A combination of these and other methods now
allow a diagnosis of AD to be established during life. However, the required techniques are
expensive, invasive, and have limited availability. A more easily accessible biomarker with
the ability to provide an AD diagnosis at early stages of disease would therefore be of great
benefit to the field. My results indicate that plasma contact system activation has the
potential to be one such biomarker. The value of contact system activation as an early
indicator of disease is supported by the correlation between CSF Aβ42 levels and plasma
HK cleavage as well as by contact system activation in pre-symptomatic individuals (Figure
5.2D, red points).
A definitive AD diagnosis during life is unfortunately of little help to the patient unless
clinically meaningful treatment is available. Approved drugs for AD currently include
acetylcholinesterase inhibitors and an NMDA receptor antagonist, both of which provide
temporary relief by managing symptoms, but do not stop the progression of the disease. In
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addition to therapeutic challenges stemming from late diagnosis, a possible reason for such
limited success is that AD is a heterogeneous disease with potentially different driving
mechanisms in different patients. Patients may therefore need therapy aimed at
mechanisms specific to their disease to provide maximum efficacy. In this regard, monitoring
the levels of plasma contact system activation could be used as a diagnostic tool to help
identify AD patients with inflammatory and thrombotic disease mechanisms. If FXII
activation is found to contribute to disease progression, identification of AD patients with this
biochemical signature may pave the way for new therapies aimed at neutralizing FXIIa, such
as anti-FXIIa antibody 3F7, which specifically blocks FXIIa activity and interferes with FXIIadriven bradykinin formation in plasma145.
6.9. Future directions
Role of Aβ-mediated prothrombotic and proinflammatory processes in AD. It will be
important to determine whether activation of FXII-dependent intrinsic coagulation and
plasma kallikrein-kinin pathways contributes to AD onset and development in vivo. The
thrombotic potential, AD pathology, and cognitive performance of AD and littermate control
mice should be assessed in the presence and absence of FXII. FXII depletion can be
accomplished by crossing AD mice with FXII null mice, which are viable and have no
obvious phenotype but are protected from thrombosis264. Thrombotic potential as measured
by CAT144 or in vivo thrombosis assays59, BBB permeability, neuroinflammatory markers,
and cognitive performance should be tested at different ages to determine if and through
what mechanisms FXII is involved. The role of Aβ in this process may be defined by
intravenous treatment of groups of mice with an anti-Aβ antibody. If FXII deficiency is
protective in AD mouse models, the relative contributions of FXI-driven coagulation and
kallikrein-driven inflammation can be determined by creating AD lines lacking FXI or
kallikrein.
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Plasma contact system activation as a biomarker for AD. Increased plasma kallikrein
activity and HK cleavage found in AD patients and mouse models (Figures 5.2-5.4) could be
an exciting potential biomarker regardless of whether Aβ-mediated FXII activation is
determined to be a causative mechanism in AD development. Increased kallikrein activity
and HK cleavage will need to be validated in a larger cohort that includes individuals with
familial and sporadic AD as well as individuals with other neurodegenerative diseases.
Furthermore, blood collection protocols will need to be optimized to take advantage of the
potential amplification of in vivo contact system activation observed in plasma from Group 1,
and standardized to minimize differences in plasma activation during collection and storage.
Most likely, HK cleavage would need to be used in conjunction with other disease markers
to serve as a diagnostic tool for AD, since FXII activation and HK cleavage may also be
features of unrelated disease states. Increased levels of FXIIa have been found in chronic
conditions such as systemic amyloidosis122 and hyperlipidemia265 as well as following acute
conditions such as ischemic stroke266 and myocardial infarction267. Increased cleavage of
HK has been observed in chronic conditions like systemic lupus erythematosus268, certain
cancers269, and during acute attacks in hereditary angioedema270. Evaluation of larger
populations would help determine appropriate cut-off values for FXII activation and HK
cleavage that may differentiate between AD and other disease states. For improved
discrimination between AD and other disease states, plasma HK cleavage should also be
tested as part of a panel of plasma components associated with AD as in 271-273. The
development of an ELISA capable of distinguishing between cleaved and uncleaved HK
would be beneficial to such studies.
Role of contact system activation in the brain parenchyma. My results demonstrating
increased levels of cleaved HK in AD patient and mouse model brain parenchyma strongly
implicate contact system activation in brain tissue. The origin of contact activation proteins in
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the AD brain is unclear. FXII and prekallikrein expression in normal brain tissue have been
reported190,192,193, but HK mRNA was only detected under pathological conditions192,194. FXII,
prekallikrein, and HK expression should be measured in AD mice and controls as a function
of age and AD pathology. If local expression is not found, the mechanisms by which HK
(and several other plasma proteins) extravasating across the BBB are retained in the AD
brain while others are not will need to be investigated. The effect of HK cleavage in brain
tissue on glial and neuronal health should also be investigated. While bradykinin released
from HK could have proinflammatory and vasoactive effects, cleaved HK itself has antiangiogenic properties, and FXII and FXIIa are signaling molecules274.
Epidemiological studies. AD risk should be assessed in individuals with deficiency in
functional FXII, FXI, HK, and prekallikrein. Based on my results and model, these individuals
would be expected to be protected from AD. By contrast, AD risk may be elevated in
individuals with gain-of-function mutations in FXII or with decreased levels of functional C1
esterase inhibitor.
Aβ-mediated contact system activation and complement. Accumulating evidence
implicates complement activation in AD275,276. Complement pathways can be activated by Aβ
directly275 or by Aβ-induced FXIIa and kallikrein activity277. It would be interesting to
determine the relative contributions of direct Aβ-mediated complement activation vs. Aβinduced, contact system-mediated complement activation in AD. This can be accomplished
by blocking FXIIa and kallikrein activity in AD mice using ASOs, inhibitors, or genetics. Most
studies have thus far focused on the role of complement in the brain parenchyma. The role
of plasma complement activation in vascular pathology and AD development should be
investigated.
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Aβ40. An interesting consideration is the role of Aβ40 (which is more abundant in the
circulation than Aβ42) in the activation of FXII-dependent processes. Preliminary results
indicate that Aβ40 can also trigger FXII-dependent FXI activation and HK cleavage in
plasma, although not as strongly as Aβ42. It is possible that the combined action of Aβ42
and Aβ40 may be additive or even synergistic in triggering these pathways.
6.10. Conclusion
Cerebrovascular dysfunction and dysregulation of CBF are early processes in AD
development, preceding Aβ plaque deposition, neuronal damage, and cognitive decline in
AD28,244,278,279. Factors modulating CBF and vascular function could therefore have profound
effects on disease onset and progression. In this thesis, I provided evidence that Aβ42 could
be a driver of cerebrovascular dysfunction through activation of FXII, the primary trigger of
both the intrinsic coagulation pathway and the kallikrein-kinin system, and through its
interaction with fibrinogen.
Because AD is a complex and multifactorial disease, it is unlikely that a single
pathogenic mechanism will emerge. The ability to identify groups of patients with AD driven
by specific mechanisms and to treat them accordingly would be a major advance in the field.
If contact system activation is found to play a causative role in AD pathogenesis, targeting
FXII, which is dispensable for hemostasis117, could provide novel therapeutic opportunities
for individuals with elevated plasma HK cleavage.
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